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This master’s thesis describes a method to prepare heteroarene-linked cycloalkenones. The 
method is a previously underutilized palladium-catalyzed coupling reaction between vinyl chlorides 
and non-activated heteroarenes. The reaction type is essentially the reverse of the Heck reaction. 
The procedure was optimized using a reaction between imidazo[1,2-a]pyridine and 3-chloro-2-
cyclohexenone. The optimized reagent system consists of Pd(OAc)2 as catalyst, PPh3 as ligand, 
K2CO3 as base, 2-ethylhexanoic acid as acid additive and toluene as solvent. A number of other 
heteroarenes and another chlorocycloalkenone were used to expand the scope of the reaction, 
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100 °C but some substrates required a higher temperature of 120 °C. Chlorocycloalkenones were 
used in a moderate excess. 
The most suitable substrates were fused imidazoles and substituted oxazoles and thiazoles. 
Yields of over 80% were obtained from several substrates and most yields ranged between 50% 
and 80%. Ester and nitrile functionalities were tolerated. Unsubstituted thiazole reacted 
unselectively at two sites. 
As such, the developed method has potential uses in small-scale medicinal chemistry and other 
fine chemical industries. The use of non-activated heteroarenes complies with the green chemistry 
principles. In addition, vinyl chlorides are conveniently synthesized and are relatively stable 
compared to other vinyl halides. 
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Tässä diplomityössä esitellään menetelmä heteroareenikytkettyjen sykloalkenonien 
valmistamiseksi. Menetelmä on aiemmin vähän käytetty palladiumin katalysoima kytkentäreaktio 
vinyylikloridien ja aktivoimattomien heteroareenien välillä. Reaktiotyyppiä voi pitää käänteisenä 
Heck-reaktioon nähden. 
Menetelmä optimoitiin käyttäen reaktiota imidatso[1,2-a]pyridiinin ja 3-kloro-2-sykloheksenonin 
välillä. Optimoidussa reagenssiyhdistelmässä oli katalyyttina Pd(OAc)2, ligandina PPh3, emäksenä 
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Useat reaktiot tuottivat yli 80 %:n saannon, ja useimmat saannot olivat 50 ja 80 %:n välillä. Esteri- 
ja nitriilifunktionaalisuudet kestivät reaktio-olosuhteissa. Substituoimaton tiatsoli reagoi epä-
selektiivisesti kahdesta paikasta. 
Menetelmä soveltuu sellaisenaan pienen mittakaavan lääkeainekemian ja muun hienokemian 
käyttöön. Aktivoimattomien heteroareenien käyttö on vihreän kemian periaatteiden mukaista. 
Lisäksi vinyylikloridit ovat helposti saatavilla ja ne ovat suhteellisen stabiileja muihin 
vinyylihalideihin verrattuna. 
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1 Introduction 
Palladium-catalyzed coupling reactions have long been recognized as some of the 
most powerful and versatile ways of forming carbon–carbon bonds. A particularly 
reliable class of these reactions is a coupling of an aryl or vinyl halide with an 
organometallic reagent. Both of the coupling partners have to be functionalized, 
which increases synthetic complexity as well as byproducts. In accordance with the 
green chemistry principles, the focus in palladium-catalyzed reactions has turned to 
reactions that do not have these limitations. Much attention has recently been paid to 
C–H activation reactions in which at least one reactive center is a simple carbon–
hydrogen bond. In 2011 alone over 500 papers were published on the topic.1 
An emerging subject in the field of C–H activation is a coupling of non-activated 
heteroarenes with vinyl halides. Vinyl heteroarenes are in themselves common 
motifs in pharmaceutical compounds; in addition, the double bond can act as a 
scaffold onto which further functionalities can be built. The novel strategy is the 
reverse of the Heck reaction which couples aryl halides with alkenes (Scheme 1). 
Another related C–H activation reaction is the Fujiwara-Moritani reaction which was 
first described using stoichiometric palladium a few years prior to the Heck reaction.2 
Later iterations use an external oxidizer which regenerates the active catalyst, hence 
the reaction is also called the oxidative Heck reaction. The reduced form of the 
oxidizer is obtained as a byproduct. 
 
Scheme 1. Palladium-catalyzed aryl–vinyl coupling reactions. Any acid byproducts are usually 
neutralized with base. X = Cl, Br, I, OTf; [M] = B(OR)2, ZnX, SnR3, MgX. 
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This thesis aims to develop a C–H activation procedure coupling heteroarenes with 
vinyl chlorides. Vinyl chlorides are uncommon coupling partners due to their low 
reactivity; however, they are usually more available and less expensive than other 
vinyl halides. Non-activated heteroarenes are also attractive substrates in cases where 
the heteroarene has no available activated analogues. The optimized procedure is 
applied to different heteroarenes and vinyl chlorides. 
The second chapter of this thesis presents potential applications of the method. 
Chapter 3 is a detailed review on the reaction class in question. Proposed 
mechanisms are presented and existing literature is discussed more closely. 
Properties unique to the reverse-Heck reaction are considered in detail and compared 
to the Heck and oxidative Heck reactions. Chapters 4 to 6 summarize the 
experimental part of the thesis.  
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2 Applications of vinyl heteroarenes 
Many active pharmaceutical ingredients contain a side chain double bond connected 
to a heteroaromatic ring. Examples of such vinyl heteroarenes are presented in Figure 
1. The examples contain a variety of heterocycles including thiophene, thiazole, 
imidazole, quinoline, pyrrole, pyridine, indole and pyrimidine as well as both 
electron-rich and electron-deficient double bonds. Ixabepilone is an amide analogue 
of the epothilones, bacterial metabolites that have been studied as potential 
anticancer drugs.3 Other examples include the antiparasitic drug pyrantel,4 the 
antihypertensive drug eprosartan,5 the antiasthmatic drug montelukast,6 the 
anticancer drugs sunitinib7 and abiraterone acetate8 and the lipid-lowering HMG-
CoA reductase inhibitors fluvastatin9 and rosuvastatin.10 
Figure 1. Pharmaceutical molecules that contain vinyl heteroarene units. 
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Modern statin drugs typically have such a side chain double while in the older types 
of statins a saturated linkage has usually provided optimal activity.11 Similarly, the 
reduced derivative of abiraterone acetate was an order of magnitude less potent than 
its precursor.8 
Some interest has also been directed toward heteroarene-coupled cyclohexenones 
which are the focus of the experimental part of this thesis. Gilbertson and co-workers 
screened multiple related small molecule inhibitors of anthrax edema factor and 
reported moderate activity (Figure 2).12 The compounds were synthesized using a 
Suzuki-type reaction with yields ranging from low to good. Bäuerle and co-workers 
developed a series of dicyanomethylene-capped oligothiophenes DCCnT that 
function as small molecule semiconductors (Scheme 2).13 Thiophene-coupled 
cyclohexenones served as important intermediates. These acceptor–donor–acceptor-
type oligomers outperformed previous derivatives and have potential applications in 
organic solar cells. 
 
Figure 2. Examples of small molecule inhibitors of anthrax edema factor screened by Gilbertson 
and co-workers.12 
 
Scheme 2. Syntheses of small molecule semiconductors DCCnT from thiophene-coupled 
cyclohexenones.13 
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3 C–H arylation of vinyl halides 
In the last couple of decades a handful of papers have been published on a new type 
of vinyl–aryl coupling reaction, C–H arylation of vinyl halides. These reactions have 
combined some of the best qualities of the existing techniques: few byproducts, 
easily obtained starting materials, good regioselectivity, and good functional group 
tolerance. Since a vinyl halide is coupled with a non-activated arene, the method has 
been called the inverse- or reverse-Heck reaction.14,15 This chapter discusses the 
reverse-Heck reaction in detail, concentrating on differences to the other Heck-type 
reactions. Although some authors have not distinguished the reverse-Heck reaction 
from the Heck reaction, it can be argued that the differences in regio- and 
stereoselectivity justify calling it its own type. 
Subchapters 3.6 and 3.7 elaborate on representative reactions that did not come up on 
previous subchapters. As the thesis mainly focuses on heteroarenes, reactions of 
arenes are discussed in a more general sense. Common strategies to achieve 
regioselectivity are discussed. 
Similar reactions have also been performed using copper16 and cobalt17 catalysts 
instead of palladium. Other palladium-catalyzed reactions have been performed 
using a copper cocatalyst18,19 or a strong organometallic base (e.g. BuLi20 or a 
Grignard reagent21). The latter types can be considered to belong to the organometal–
halide coupling reactions. This thesis focuses on reactions using palladium as the 
sole metal catalyst. Some borderline cases using an intermediate strength base (e.g. t-
BuOLi22) are included. 
3.1 Proposed mechanisms 
Two essentially different mechanisms have been proposed for the reverse-Heck 
reactions: one catalyzed by Pd0 (Scheme 3) and the other catalyzed by PdII (Scheme 
4). The actual C–H activation step (metalation-deprotonation) and other details that 
affect the regio- and stereochemical outcome are discussed in the following 
subchapters. In the presented general catalytic cycles spectator ligands (e.g. solvent 
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or PPh3) are omitted and an unspecified base B is present. Base is however not used 
in some actual procedures: for example, Daugulis and Zaitsev used AgOTf to 
precipitate the halide.15 Fagnou and co-workers also reported that the addition of a 
soluble proton transfer agent such as pivalic acid significantly increased reactivity in 
C–H heteroarylations of aryl halides.23 
The Pd0 mechanism (Scheme 3) was proposed by Trauner and Hughes24 based on the 
work on aryl–aryl coupling reactions by Miura and co-workers.25 Later similar 
mechanisms have been proposed by Berteina-Raboin and co-workers,26 Lautens and 
Chai,27 Cramer and Albicker,28 Li and co-workers,29 Chen and co-workers30, Zhang 
and co-workers31 and Xi and co-workers.32 The mechanism consists of oxidative 
addition of the vinyl halide to Pd0 to generate a PdII intermediate (I), C–H activation 
of the heteroarene (II and III) and reductive elimination (IV) to yield the product 
and regenerate the Pd0 catalyst. Pd0 is in the first place generated from PdII(OAc)2 via 
reduction by a phosphine ligand, an amine or an olefin.33 The mechanism resembles 
the Heck reaction34 in the oxidation state of palladium and the order in which the C–
X and C–H bonds are activated, however the exact steps differ: the Heck reaction 
requires syn addition of palladium to the alkene, C–C bond rotation and syn β-
hydride elimination. 
 
Scheme 3. The Pd0 mechanism for the heteroarylation of a vinyl halide. Y, Z = heteroatoms. 
The PdII mechanism (Scheme 4) has been proposed by Daugulis and Zaitsev,15 
Bouillon and co-workers35 and Ye and co-workers.36 It consists of C–H activation of 
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the heteroarene (I and II), syn insertion to the vinyl halide (III) and anti β-halide 
elimination (IV). The oxidation state of palladium stays the same throughout the 
cycle. The mechanism resembles that of the oxidative Heck reaction2 except for the 
last step: the oxidative Heck reaction requires C–C bond rotation, syn β-hydride 
elimination and reductive elimination to afford Pd0 which is oxidized to PdII by an 
external oxidizer. The reverse-Heck reaction does not require an external oxidizer 
because the heteroatom ligand can eliminate without reduction. 
 
Scheme 4. The PdII mechanism for the heteroarylation of a vinyl halide. Y, Z = heteroatoms. 
An important difference between the mechanisms is the way the palladium complex 
adds to the vinyl halide. In the Pd0 mechanism the double bond stays untouched 
while in the PdII mechanism the palladium complex inserts across the double bond. It 
is easy to see that in the Pd0 mechanism the regio- and stereochemistries of the 
double bond stay unchanged but the same also applies to the other mechanism as will 
be discussed in the following subchapters. Experimental results support this retention 
hypothesis so both mechanisms are possible. 
The exact nature of the C–H activation step depends on the base, additive and the 
(hetero)arene. In Scheme 5 two possible C–H activation pathways are presented: the 
concerted metalation-deprotonation (CMD) and the electrophilic metalation-
deprotonation (EMD).37 A carboxylic acid R’COOH is added as a proton transfer 
agent to form the six-membered transition state; a four-membered transition state is 
also possible with other bases. In the one-step CMD pathway, the aromatic C–H 
bond is cleaved at the same time as the Pd–C bond is formed. The most acidic C–H 
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bond is typically activated. In the two-step EMD pathway, the (hetero)arene first 
attacks in an SEAr fashion to palladium, and the C–H bond is cleaved only after the 
Pd–C bond is formed. The C–H bond is activated at the most nucleophilic site of the 
arene. The reactions can thus lead to different products depending on the C–H 
activation mechanism if the most acidic and the most nucleophilic sites differ. 
Electron-deficient arenes are often thought to react via the CMD pathway and 
electron-rich arenes via the EMD pathway. However, the issue may not be so 
obvious as Fagnou and co-workers demonstrated that a wide range of (hetero)arenes, 
including electron-rich ones, proceed via the CMD pathway.38  
 
Scheme 5. Two potential pathways for C–H activation. Y, Z = heteroatoms. 
3.2 Regiochemistry of the double bond 
The traditional Heck reactions usually proceed smoothly with alkenes substituted 
with electron-withdrawing groups. On the other hand, electron-neutral or electron-
rich alkenes have often yielded a wide variety of side-products such as diarylated 
products, regioisomers, double bond isomers and mixtures of cis and trans isomers.39 
Some useful regio- and stereocontrolled Heck reactions have been developed but 
they may require extreme conditions or intricate catalyst systems. In contrast, the 
reverse-Heck reaction is in many ways inherently regio- and stereospecific. These 
two subchapters discuss the regiochemistry of the vinyl halide coupling partner and 
the stereoselectivity of the resulting double bond. 
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The existing coupling methods have little control over the heteroaryl addition site 
when using unpolarized vinyl compounds. For example, an oxidative Heck reaction 
between an imidazo[1,2-a]pyridine and styrene reported by Berteina-Raboin and co-
workers (Scheme 6a) led to two double bond isomers 6 and 7.40 In contrast, reverse-
Heck reactions appear to always couple with the halide-bearing carbon atom: for 
example, the reaction between an oxazole and β-bromostyrene reported by Piguel 
and co-workers produced the desired β-coupling product 10 in good yield (Scheme 
6b).22 Even the other product 13 could be made via the reverse-Heck reaction as 
reported in another article by Berteina-Raboin (Scheme 6c).26 
 
Scheme 6. a) Heteroarylation of styrene via the oxidative Heck reaction.40 b) and c) 
Heteroarylations of bromostyrenes via the reverse-Heck reaction.
22,26 
Another regiochemical difference is in the position of the double bond. In the Heck 
and oxidative Heck reactions, syn β-hydride elimination next to the inserted group is 
possible only after a C–C bond rotation. With cyclic olefins (Scheme 7a) this rotation 
is not possible and the elimination occurs at the opposite side, forming the allylic 
product B.41 Moreover, the palladium hydride can add to the allylic product and 
isomerize it to homoallylic product C, a process known as double bond migration. 
The vinylic products A have only been achieved with rather specific catalystligand 
systems and long reaction times42 or with cyclic enones via a palladium enolate 
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intermediate.43 However, regioselectivity is not a problem with the reverse-Heck 
reactions. Unlike hydrides, heteroatoms are eliminated anti which is convenient 
because the halide always ends up opposite to the palladium after syn insertion 
(Scheme 7b). The anti arrangement of β-heteroatom elimination was confirmed 
experimentally by Lu and Zhu44 and with DFT calculations by Lin and co-workers.45 
In fact, no competitive syn β-hydride elimination occurred at all when there was a 
good anti β-leaving group.44 Chen and co-workers obtained coupling products from 
vinyl iodides of various ring sizes in good to excellent yields (Scheme 8), with the 
exception of the five-membered ring (product 15).14 Regioselectivity in the aromatic 
ring was achieved using a chelating picolinamide group in the ortho position (see 
Section 3.5 for more information). 
 
Scheme 7. a) The Heck reaction of cyclohexene. b) The reverse-Heck reaction of cyclohexenyl 
iodide. 
 
Scheme 8. Chelate-assisted reverse-Heck reactions with various cyclic vinyl iodides.14 
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3.3 Stereochemistry of the double bond 
Heck reactions typically have an excellent trans selectivity with monosubstituted 
alkenes. The molecule is free to rotate in such a conformation that places the 
substituents farthest from each other, after which syn β-hydride elimination leads to 
the trans product (Scheme 9).39 For this reason the cis product is usually difficult to 
obtain. It can in some cases be favored with chelating ligands: for example, Milstein 
and co-workers managed to synthesize stilbene in a 7:81 E/Z ratio using 1,3-
bis(diisopropylphosphino)propane (dippp) as ligand.46 
 
Scheme 9. The Heck reaction of a monosubstituted alkene leading to the trans product. 
In contrast, in reverse-Heck reactions the anti β-heteroatom elimination is always 
possible right after insertion to the double bond (Scheme 7b) so the reaction 
preserves whichever configuration the double bond was in. Indeed, excellent cis 
selectivities have been obtained using (Z)-β-bromostyrene derivatives (Table 1) by 
Piguel and co-workers22 and Hoarau and co-workers.47 The cis selectivities were 
consistently over 90% and most trans products were explained by contamination in 
starting materials. According to Piguel, any formed trans product was the result of 
thermal isomerization. A compromise had to be made between conversion and 
isomerization as prolonged heating resulted in larger ratios of the trans product. On 
the other hand, Hoarau obtained essentially the same Z/E ratio as in starting materials 
after 18 hours of reaction and isomerization was not significant (product 25). 
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Table 1. Reactions between substituted oxazoles and various (Z)-β-bromostyrene derivatives by 
Piguel and co-workers22 and Hoarau and co-workers.47 
 
Yields and Z/E ratios in starting materials and products are presented. 
3.4 Effect of the (pseudo)halide 
Heck reactions using aryl chlorides are typically considerably slower than those 
using aryl bromides and iodides. The rate of oxidative addition is limited by the bond 
dissociation energy.48 For example, the experimental C–X bond dissociation energies 
in phenyl halides are 97, 84 and 67 kcal/mol for Cl, Br and I.49 The limitations are 
similar in reverse-Heck reactions. The proposed mechanisms require either oxidative 
addition to a C–X bond (Scheme 3) or β-elimination of a halide (Scheme 4). The 
bond dissociation energies of vinyl halides are slightly lower than those of aryl 
halides: for example, 91 and 81 kcal/mol for X = Cl and Br in CHXCH2.
49 Despite 
this advantage, published reactions of vinyl chlorides are uncommon. Chlorides 
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would be very attractive substrates because they are usually more available and less 
expensive to make than other halides.50 The lower reactivity also makes them more 
shelf-stable. For these reasons vinyl chlorides were chosen as substrates for the 
experimental part of this thesis. 
Aryl triflates are the most common pseudohalides in Heck reactions and their 
reactivities are similar to those of aryl bromides.48 On the other hand, reverse-Heck 
reactions with vinyl triflates have been performed at exceptionally low temperatures 
and with short reaction times. In 2002 Willis and co-workers published an 
intramolecular arene–vinyl triflate coupling that was conducted at 50 °C (Scheme 
10a).51 In 2009 Cramer and Albicker published a similar enantioselective reaction 
occurring at room temperature in only three hours, yielding the product in excellent 
yield and enantioselectivity (Scheme 10b).28 Since this striking difference in 
performance between triflates and halides is not explained by relative reactivities, 
another possibility is the mechanism. The Heck reaction is known to occur via either 
a neutral or a cationic pathway.48 In the neutral pathway (analogous to steps II and 
III in Scheme 3) the halide is coordinated to the palladium complex during the C–H 
activation, which is the usual case. However, non-coordinating counterions such as 
triflates initiate the cationic pathway in which the counterion is dissociated prior to 
the C–H activation, making a cationic palladium complex.48 Cramer and Albicker 
proposed that this cationic complex should undergo rapid association with a 
carboxylate ion to form the crucial cyclic intermediate in Scheme 5.28 
Another documented approach to initiate the cationic pathway is to use a silver salt 
as a halide scavenger.52 Daugulis and Zaitsev used silver triflate to scavenge the 
bromide (Scheme 17a, Section 3.7).15 The reaction was complete after 1.5 hours at 
90 °C. The coupling was unsuccessful using sodium triflate. When using iodide 
substrates, silver salts can also overcome the catalyst poisoning effect caused by 
accumulation of iodide.53 
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Scheme 10. Intramolecular reverse-Heck with vinyl triflates by Willis and co-workers51 and 
Cramer and Albicker.28 L* is a TADDOL-based chiral phosphine ligand. 
3.5 Regiochemistry of the arene 
This section discusses factors that govern the regiochemical outcome of C–H 
activation in heteroarenes and arenes. Most of the research on the subject has been 
done in the context of aryl halide arylations. The principles are assumed to apply to 
vinyl halide arylations as well. 
Heteroarenes are typically inherently selective in specific sites. These sites 
correspond to the most nucleophilic or acidic sites depending on the C–H activation 
mechanism (Section 3.1). The most favorable C–H activation sites of monocyclic 
electron-rich heteroarenes are compiled in Figure 3, as reported by Gorelsky and co-
workers,37 Ess and co-workers54 and Fagnou and Leclerc.55 Five-membered 
heteroarenes are predominantly activated at the C2 or C5 site when the heteroatom 
with a delocalized lone pair is assigned to 1. Similarly, pyridine N-oxide and diazine 
N-oxides are activated at the C2 or C6 site. The regioselectivity is also influenced by 
any ring fusions and substituents present on the heterocycle and used reagents but the 
C2/C5 selectivity holds true remarkably well. The C2 and C5 sites often exhibit 
comparable reactivity and it is a difficult task to differentiate between them if both 
are unsubstituted. However, in some cases carefully selected reagents and conditions 
have afforded the C2 or C5 arylated products in excellent selectivities.56 
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Figure 3. Most favorable positions for C–H activation of electron-rich heteroarenes. Bold C–H 
bonds are preferentially activated. 
Some attention has been directed toward C3 and C4 activation of heteroarenes as 
reviewed by Doucet and co-workers.57 Most often C3/C4 selectivity has been 
achieved by blocking the more favorable sites or in intramolecular reactions. Also, 
pyrroles and indoles have been selectively activated at the C3 site by using bulky or 
cationic substituents on the nitrogen. For example, Sames and co-workers reported 
that the congested MgClTMEDA-substituted indole gave almost exclusively the C3 
product in 96% yield (Scheme 11).58 
 
Scheme 11. C3 arylation of indole with a bulky cationic substituent. Reaction yield based on 
PhBr.58 
In contrast to heteroarenes, benzene rings usually have little control over C–H 
activation regioselectivity. There are limited cases in which a simple arene has been 
selectively functionalized as reviewed by Glorius and co-workers.59 In other cases, 
reliable selectivity has been achieved with either coordinating groups or blocking 
groups. Coordinating groups are arene substituents that coordinate to the palladium 
complex and deliver the coupling partner to a specific site, almost always the ortho 
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position. Common coordinating groups are amides and pyridines.59 Another strategy 
is to block all but one site with inert substituents. Popular examples are 
perfluorobenzenes which have often been used in aryl–aryl coupling reactions.60 The 
role of the fluoride substitution is twofold: besides blocking other possible activation 
sites, the substituents withdraw electron density from the ring and thus make it more 
reactive in the CMD pathway.60 
3.6 Reactions with heteroarenes 
Open-chained haloalkenes are some of the most studied substrates in reverse-Heck 
reactions. As discussed in Section 3.2, simple alkenes are rarely usable in traditional 
Heck-type reactions which would be an incentive to develop their reactions. 
Published heteroarylations of aliphatic vinyl halides are compiled in Table 2 with 
reagents, conditions and two representative products. The reactions have given fair to 
excellent yields (51–91%) and good regioselectivities with respect to both the vinyl 
compound and the heteroarene. The only exception is product 38 which was 
accompanied with 28% of the double coupling product.47 Reaction conditions are 
usually harsh with temperatures over 100 °C and long reaction times, but in some 
cases the reaction was complete in only 2 or 4 hours. Polar solvents and carbonate 
bases are typical as well. The vinyl halide is usually a bromide which is a 
compromise between availability and reactivity. For example, vinyl chlorides were 
not reactive under Piguel’s conditions (Entry 4).22 However, Hoarau and co-workers 
have reported two single reactions with vinyl chlorides yielding 91% and 65% 
(products 37 and 41).47,61 In fact, vinyl chloride seemed to be a more selective 
coupling partner and did not yield any double coupling product. Hoarau’s conditions 
were later used by Fürstner and co-workers in their total synthesis of enigmazole A, a 
macrolide isolated from marine sponge Cinachyrella enigmatica (Scheme 12).62 
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Table 2. Heteroarylations of various open-chained haloalkenes. 
Entry Halidea Reagentsa Conditions Productsb 
126 
Br 
(2) 
Pd(OAc)2 (0.2) 
AsPh3 (0.4) 
Ag2CO3 (2) 
DMF+Et3N 
130 °C 
2 h  
33, 71% 
 
34, 56% 
263 Br (0.5) 
PdCl(C3H5)dppb 
(0.05) 
Cs2CO3 (2) 
DMF 
140/120 °C 
20 h  
35, 51% 
 
36, 58% 
347 Cl/Br (2) 
Pd(OAc)2 (0.05) 
CyJohnPhos 
(0.1) 
Cs2CO3 (2) 
dioxane 
110 °C 
18 h  
37, 91% 
 
38, 55%c 
422 
Br 
(2) 
Pd(PPh3)4 (0.05) 
t-BuOLi (2) 
dioxane 
120 °C 
4 h  
39, 71% 
 
40, 66% 
561 Cl/Br (3) 
Pd(OAc)2 (0.05) 
CyJohnPhos 
(0.1) 
Cs2CO3 (5) 
dioxane 
120 °C 
18 h 
 
41, 65% 
 
42, 60%d 
Bold bonds are formed. Vinyl halide coupling partners are specified in the Halide column. 
a Equivalents in parentheses. b Isolated yields based on the limiting starting material. 
c 2,5-divinylated product isolated in 28% yield. d mNP = 3-nitrophenyl. 
 
Scheme 12. Heteroarylation of a vinyl iodide as a step in the total synthesis of enigmazole A.62 
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In contrast to electron-neutral alkenes, alkenes with electron-withdrawing groups 
usually react cleanly in Heck reactions. However, their use in reverse-Heck reactions 
of heteroarenes is rare. The only close example is an intramolecular reaction between 
enone triflate and benzofuran reported by Trauner and Hughes in 2004 (Scheme 
13).24 Compared to the triflate coupling reactions reported by Willis and co-workers 
and Cramer and Albicker (Scheme 10), this reaction needed a higher temperature (90 
°C) and reaction time (36 h). The product was used in the synthesis of (–)-frondosin 
B, the enantiomer of a marine terpenoid that has possible applications against 
autoimmune disorders. 
 
Scheme 13. Intramolecular heteroarylation of a vinyl triflate as a step in the total synthesis of 
(–)-frondosin B.24 
Huang and co-workers used intramolecular reverse-Heck reactions between 1,2,3-
triazole and vinyl iodide as part of their synthesis of 4-alkylidene-5,6-dihydro-4H-
pyrrolo[1,2-c][1,2,3]triazoles (Table 3).64 Previous syntheses of pyrrolotriazoles had 
been limited and involved thermal intramolecular cycloadditions. The products were 
obtained in fair to very good yields (52–85%). However, substrates containing a 
vinyl hydrogen (R = H) only gave alkyne products via elimination. Tetrabutyl-
ammonium chloride was presumably added as a phase transfer catalyst. 
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Table 3. Intramolecular reverse-Heck reactions yielding pyrrolotriazoles.64 
 
Product R / R’ / R’’ Time (h) Yield (%) 
48 Ph / Ph / C5H11 20 85 
49 Ph / Ph / CH2OMe 19 52 
50 p-ClC6H4 / p-ClC6H4 / C5H11 22 58 
51 p-FC6H4 / p-FC6H4 / C5H11 22 70 
52 Me / Ph / C5H11 20 71 
Several research groups have used gem-dibromovinyl compounds in one-pot 
reactions that combine intramolecular reverse-Heck reactions with other palladium-
catalyzed coupling reactions. The combination is exceptionally favorable for several 
reasons. The trans halogen is less sterically hindered and thus more reactive in 
intermolecular reactions while the intramolecular heteroarene can only react with the 
cis halogen. Besides, gem-dihalovinyl compounds are more reactive toward 
palladium complexes than the corresponding monohalovinyl compounds.27 
Lautens and Chai were the first to report a one-pot reverse-Heck–Suzuki reaction in 
2009 (Scheme 14, upper arrow).27 Syntheses of substituted pyrrole[1,2-a]quinolines 
(e.g. 56) succeeded in good to excellent yields from dibromovinyl pyrrole system 53. 
Various Suzuki reagents including aryl, alkyl and alkenyl boronic acids gave good 
results. The indole derivative 54 also gave the product 57 in good yield; however, 
other ring systems such as furans, thiophenes, pyrazoles and tetrazoles were not 
successful. Water was observed to have an important role on the rate of the Suzuki 
reaction but not on the rate of the reverse-Heck reaction. 
Later, Wu and co-workers targeted similar products in their one-pot double reverse-
Heck reaction (Scheme 14, lower arrow).65 The intermolecular coupling partners 
were a wide range of non-activated perfluorobenzenes, other electron-deficient 
benzenes and a tetrafluoropyridine. The ligand was changed to RuPhos, another 
Buchwald ligand (see Figure 5 in Section 4.2 for structures). Yields ranged from 
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good to excellent: for example, the perfluorinated derivatives of Lautens and Chai’s 
products (59 and 60) were obtained in comparable yields. Reverse-Heck reactions of 
perfluorobenzenes are discussed further in the next section. 
 
Scheme 14. One-pot coupling reactions of gem-dibromovinyl compounds reported by Lautens 
and Chai27 and Wu and co-workers.65 
Chen and co-workers developed an intramolecular one-pot reverse-Heck–amination 
procedure using gem-dibromovinyl compounds.30 The amination first occurred at a 
lower temperature using potassium carbonate, after which the palladium-catalyzed 
coupling reaction was performed immediately without work-up. The intramolecular 
reverse-Heck reaction was successfully performed on pyridine N-oxide, furan, 
thiophene, indole, quinoline and various substituted benzenes (Table 4). Furan and 
thiophene were also coupled on the less favorable C3 site (products 64 and 65). 
Pyridine coupled unselectively at the C2 and C4 sites. Interestingly, the amine 
coupling occurred on the opposite side of the double bond to the bromide (Scheme 
15). The expected product 72 could have provided access to derivatives of 
camptothecin, a quinolone alkaloid which has exhibited anticancer activity. Several 
camptothecin derivatives have been approved for use in cancer chemotherapy.66 
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Table 4. One-pot reverse-Heck–amination procedure reported by Chen and co-workers.30 
 
 
Scheme 15. Site of amination in Chen’s one-pot reaction procedure. The desired product 
resembles the camptothecin framework.30 
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Li and co-workers developed a similar sequential one-pot reaction combining the 
reverse-Heck reaction and nucleophilic addition to alkyne (Table 5).29 The vinyl 
bromide intermediate is first formed using potassium carbonate, after which an 
aromatic C–H bond is activated using a typical palladium catalyst system. Furan and 
thiophene were activated at the less favorable 3-position (products 74 and 75). In 
addition, various substituted benzenes were used. Asymmetric meta-substituted 
benzenes were not selective and yielded mixtures of products. Urabe and co-workers 
have also studied similar reactions between sulfonamides and bromoacetylenes.67,68 
Table 5. One-pot nucleophilic addition–reverse-Heck reaction reported by Li and co-workers.29 
 
Reverse-Heck reactions have also been developed for dihalogen compounds that do 
not have a geminal relationship. For example, Doucet and co-workers reported a 
double coupling reaction of 1,2-dichloroperfluorocyclopentene (Table 6).69 Various 
thiazoles, thiophenes and furans were employed to form the symmetric diarylated 
products. Chloro- and bromosubstituted thiophenes were successfully coupled 
without cleavage of the arene–halogen bond (e.g. product 85). The diarylethene 
products function as molecular switches due to their controllable cyclization upon 
UV light irradiation. For example, product 83 switched to the closed form 88 after 
irradiation with 350 nm UV light and was regenerated after irradiation with 450 nm 
visible light (Scheme 16). 
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Table 6. Syntheses of diarylethene derivatives reported by Doucet and co-workers.69 
 
For each product are shown the starting material and the coupling site. 
a PdCl(C3H5)dppb (0.05 eq) as catalyst. b Reaction time 24 h. 
 
Scheme 16. Switching between the open and closed forms of product 83. 
Xi and co-workers used the reverse-Heck method in a novel indolizine synthesis 
from pyrroles and 1,4-dibromo-1,3-butadienes (Table 7).32 The mechanism involves 
an intermolecular C–N coupling followed by an intramolecular reverse-Heck 
reaction. The procedure worked well with an asymmetrically substituted butadiene 
(product 91) as the amination took place selectively at the alkyl-substituted vinyl 
bromide. However, asymmetric methyl pyrrole-3-carboxylate gave products 92 and 
93 as an inseparable 1:1 mixture. Interestingly, a styrene-type dibromide containing 
both an aryl and a vinyl bromide gave product 95 as a single isomer. Apparently 
amination of the aryl bromide took place first, even though vinyl bromides are 
 24 
 
generally more reactive than aryl bromides. The crowded cyclopentadiene phosphine 
ligand 89 gave significantly better yields than any of the other tested ligands, 
including PPh3 and CyJohnPhos. 
Table 7. Syntheses of substituted indolizines reported by Xi and co-workers.32 
 
3.7 Reactions with arenes 
Directing groups provide some of the most common ways of making regioselective 
reverse-Heck reactions of benzene derivatives. Some approaches are compiled in 
Scheme 17. Daugulis and Zaitsev used an acetamide substituent which coordinates to 
the palladium complex through the oxygen atom (Scheme 17a).15 Another commonly 
used simple amide is pivalamide which was used by Daugulis and Zaitsev as well as 
by Bouillon and co-workers.35 Chen and co-workers used a benzyl picolinamide 
which coordinates to the catalyst through two nitrogen atoms (Scheme 17b).14 A 
related quinolyl benzamide substrate was used by Ye and co-workers in their 
efficient aryl–glycal coupling procedure (Scheme 17c).36 Ye’s ligand was an unusual 
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amino acid derivative which led to high monoselectivity. In other cases, reagents and 
conditions were similar to those used in heteroarene reactions. 
 
Scheme 17. Different ortho-directing groups used in reverse-Heck reactions.  
Perfluorobenzenes are popular substrates in aryl–aryl coupling reactions but their use 
in reverse-Heck reactions is less common. Besides Wu and co-workers (Scheme 14), 
Zhang’s research group has also studied reactions of perfluorobenzenes with vinyl 
halides (Scheme 18).31 In addition to pentafluorobenzene, two common derivatives 
were used to give the trifluoromethylated product 103 and the methoxylated product 
104 in very good yields. Adamantanecarboxylic acid (AdCOOH) was used as a 
proton transfer agent. A single coupling reaction of pentafluorobenzene with 1-
chlorocyclopentene was also reported by Kwong and co-workers.70 
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Scheme 18. Perfluorobenzylations of a vinyl triflate.31 
Intramolecular reactions are a third type of reliable regioselective reactions of arenes. 
For example, You and co-workers synthesized a series of planar ferrocene 
derivatives via intramolecular ortho coupling with a vinyl bromide (Scheme 19).71 
As the vinyl bromide tether is too short to reach any other site, only one regioisomer 
is observed. Using (R)-BINAP as a chiral ligand afforded the products practically as 
single enantiomers. In this case, addition of water had a positive effect on the 
reverse-Heck reaction rate.  
 
Scheme 19. Intramolecular coupling reactions of ferrocenes by You and co-workers.71 
Other intramolecular reactions between arenes and vinyl bromides have been 
reported by Grigg and co-workers,72 Willis and co-workers73 and Ohgane and co-
workers.74  
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4 Results and discussion 
This chapter summarizes the experimental work that was done on the thesis. The aim 
was to develop a widely applicable method for coupling heteroarenes with vinyl 
chlorides. Once a suitable model reaction had been optimized, the scope of the 
method was expanded with a number of different heteroarenes and another vinyl 
chloride. Experimental procedures and analysis data are presented in Chapter 6. 
4.1 Model reaction 
The reaction between imidazo[1,2-a]pyridine 107 and 3-chloro-2-cyclohexenone 108 
(Scheme 20) was chosen as the model reaction. The reagent system has been proven 
to be applicable for several C–H activation reactions in our laboratory: 
tricyclohexylphosphine (PCy3) as ligand, 2-ethylhexanoic acid (EHA) as additive 
and potassium carbonate as base.75,76 The unoptimized reaction gave a promising 
58% yield and 73% conversion measured with LC and the product 109 was isolated 
as a yellow solid in 23% yield after careful purifications. The chromatogram was 
reasonably clean and the components were sufficiently resolved so the reaction was 
considered well suited for optimization. 3-Chloro-2-cyclohexenone was found to be 
stable for months when stored in a freezer. 
 
Scheme 20. The unoptimized model reaction. The used numbering system is shown. 
The product was obtained as a single isomer, although 1H-NMR showed traces 
(<5%) of a similar compound which is possibly the other regioisomer. The obtained 
isomer was identified using NOESY (Appendix 2). A nuclear Overhauser effect was 
observed between the vinylic proton and one of the pyridine protons as well as the 
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allylic protons and the imidazole proton (Figure 4). These effects confirm that the 
vinyl chloride coupling occurred at the imidazole C3 position. In contrast, no NOE 
was observed between the allylic and pyridine protons or between the vinylic and 
imidazole protons. The product is thus evidently locked in the s-trans conformation. 
This is an interesting result that warrants detailed conformational analysis. 
 
Figure 4. The major isomer and its conformation were determined by NOESY. 
When the reaction was exposed to a too high oxygen concentration, a phenol product 
was observed (Scheme 21). This product was isolated as a white solid in 36% yield 
using the unoptimized conditions. The side reaction was minimized by careful 
flushing with inert gas, but the phenol product quickly formed whenever heating was 
continued in the presence of oxygen. The reaction corresponds to the catalytic 
Saegusa-Ito oxidation but interestingly it is very favorable even without the 
commonly used silyl enol ether intermediate.77 The synthetic significance of the 
reaction was duly noted but for now, it was considered an unwanted side reaction. 
 
Scheme 21. Proposed pathway to the phenol product. An in situ formed enol is oxidized by PdII 
which is regenerated by oxygen. 
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4.2 Optimization of reaction conditions 
The performed optimization reactions are summarized in Tables 9 and 10. Yields of 
the desired product and phenol side-product and conversions of imidazo[1,2-
a]pyridine are reported. The chromatographic analysis is explained in Appendix 1. 
Structures of acid additives and complex ligands are presented in Figure 5. 
First, the significance of each component was confirmed. An experiment without a 
catalyst (Entry 2) gave no product so the reaction is palladium-catalyzed. An 
experiment without ligand resulted in more phenol byproduct than the desired 
product (Entry 3) and an experiment without acid additive resulted in a low 
conversion (Entry 4). The ligand effect is an interesting result and suggests that 
oxidation of the product to phenol occurs even at low oxygen concentrations but 
requires a phosphine-free palladium complex. When a ligand is used, the phenol 
product is observed only at high oxygen concentrations when phosphines are 
oxidized to phosphine oxides. 
Alternative solvents, bases, additives and ligands were screened using a design of 
experiments (DoE) approach which allows a wide exploration of the chemical space 
with few experiments. A DoE software (JMP 13) was used to plan a 16-experiment 
design (Entries 7 to 22) from the selected components (Table 8). The components 
were compiled from similar reactions in the literature and from own experience. In 
order to simplify the design and reduce redundant experiments, multiple related 
components (e.g. Cs2CO3 in addition to K2CO3) were not included; instead, they 
were tested during a second iteration for only the most promising components. Some 
less probable ligands were tested separately (Entries 5 and 6). The only non-
phosphine ligand, bipy, produced the phenol which supports the hypothesis that the 
oxidation is inhibited by phosphine ligands. 
 
 
 
 30 
 
Table 8. Components selected for the experimental design. 
Solvent Base Additive Ligand 
toluene K2CO3 EHA PCy3 
NMP K3PO4 PivOH PPh3 
DMF KOAc AdCOOH CyJohnPhos 
anisole DIPEA  cataCXium A 
dioxane    
 
 
Figure 5. Structures of acid additives and complex ligands. 
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Table 9. Optimization of reaction components. 
 
Entry Solvent Base Additive Ligand Yield (%)a Conv. (%)a 
1 toluene K2CO3 EHA PCy3 58. (3) 73 
2b toluene K2CO3 EHA PCy3 0 n/a 
3 toluene K2CO3 EHA none 27. (37) 91 
4 toluene K2CO3 none PCy3 30 40 
5 toluene K2CO3 EHA dppb 22 22 
6 toluene K2CO3 EHA bipy 39. (34) 95 
7 toluene DIPEA AdCOOH CyJohnPhos 2 9 
8 toluene K3PO4 AdCOOH cataCXium A 27 34 
9 toluene KOAc PivOH PPh3 42 61 
10 NMP K2CO3 AdCOOH PCy3 66 68 
11 NMP DIPEA PivOH PPh3 10 12 
12 NMP KOAc EHA cataCXium A 71 78 
13 DMF K2CO3 EHA PPh3 21 34 
14 DMF DIPEA AdCOOH cataCXium A 2 10 
15 DMF K3PO4 PivOH PCy3 3 2 
16 DMF KOAc AdCOOH CyJohnPhos 53 56 
17 anisole K2CO3 PivOH cataCXium A 54 66 
18 anisole K3PO4 EHA CyJohnPhos 51 50 
19 anisole KOAc AdCOOH PCy3 2 5 
20 dioxane K2CO3 PivOH CyJohnPhos 56 56 
21 dioxane DIPEA EHA PCy3 1 5 
22 dioxane K3PO4 AdCOOH PPh3 57 67 
23 NMP K2CO3 EHA CyJohnPhos 66 68 
24 toluene K2CO3 EHA CyJohnPhos 60 60 
25 xylenes K2CO3 EHA CyJohnPhos 60 62 
26 CPME K2CO3 EHA CyJohnPhos 57 63 
27 NMP Cs2CO3 EHA CyJohnPhos 13 29 
28 NMP K2CO3 EHA Sphos 60 69 
29 NMP K2CO3 EHA Xphos 14 14 
30 NMP K2CO3 EHA RuPhos 59 59 
a Chromatographic results (see Appendix 1). Phenol products in parentheses. b No catalyst. 
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The yields obtained from the screening experiments (Entries 1 and 7–22) were 
collected in the DoE software and a Standard Least Squares model was fit into the 
data. According to the prediction profiles (Figure 6) the best combination is NMP, 
K2CO3, EHA and CyJohnPhos. NMP and dioxane are both hazardous solvents so 
toluene was kept as an option. Acid additives performed identically and EHA was 
selected because it is inexpensive and easy to use being a liquid at room temperature. 
Another set of experiments was run using related solvents, another carbonate base 
and other Buchwald ligands (Entries 23 to 30). However, none of the solvents or 
ligands gave significantly better results than the original conditions. Cesium 
carbonate (Entry 27) gave a surprisingly low conversion considering it has often 
been used in similar reactions (Table 2, Section 3.6). 
 
Figure 6. Prediction profiles and the best predicted reagent combination. 
Overall, the results show that there is little difference between the performances of 
the best solvents and ligands. Toluene was chosen as the solvent because it is easy to 
evaporate and relatively green.78 Triphenylphosphine is by far the least expensive 
ligand so it was taken into further consideration. By increasing the ratio of vinyl 
chloride to heteroarene, the conversion could be increased (Table 10, Entries 31–33). 
However, the formation of a C2-C3 double coupling product led to decreased yields 
with vinyl chloride equivalents over 1.5. By using the bulkier ligand CyJohnPhos, 
this side product could be avoided altogether. Catalyst loading could be lowered to 
2% with no decrease in activity or selectivity (Entries 32, 34 and 35) so the higher 
price of the ligand became less of a problem. Using these conditions on a 3 mmol 
scale, the product 109 was isolated in 86% yield (Entry 39). 
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With most other substrates the use of CyJohnPhos resulted in drastically reduced 
conversions. In contrast, PPh3 and PCy3 performed well and almost identically. 
Triphenylphosphine was recognized as the most widely applicable ligand. 
Table 10. Optimization of starting material ratio, ligand and catalyst loading. 
 
Entry 108 eq Ligand Pd(OAc)2 eq Ligand eq Yield (%)a Conv. (%)a 
31 1 PPh3 0.05 0.15 55 82 
32 1.5 PPh3 0.05 0.15 63 98 
33 2 PPh3 0.05 0.15 56 100 
34 1.5 PPh3 0.03 0.09 64 97 
35 1.5 PPh3 0.02 0.06 68 99 
36 1.3 PPh3 0.02 0.06 71 88 
37 1.3 CyJohnPhos 0.02 0.06 75 89 
38 1.3 CyJohnPhos 0.01 0.03 66 90 
39b 1.5 CyJohnPhos 0.02 0.06 85 86 
a Chromatographic results (see Appendix 1). b On 3 mmol scale. Isolated yield 86%. 
Aryl scrambling is a well-known side reaction that sometimes occurs in palladium-
catalyzed coupling reactions when triphenylphosphine is used as a ligand.79 After 
oxidative addition, the aryl or vinyl group can be exchanged with one of the phenyl 
groups in the ligand (Scheme 22). The reaction continues normally, resulting in 
phenyl coupling product 111. Only traces of these products were observed in the 
experiments) so aryl scrambling does not appear to be significant under these 
conditions. 
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Scheme 22. Formation of a phenyl coupling product via aryl scrambling. 
4.3 Scope and limitations 
The performance of the optimized procedure was examined using different 
heteroarenes (Table 11). The coupling reactions were performed on 3 mmol or 0.5 
mmol scale. All products were isolated and purified with flash chromatography. 
Fair to excellent yields (61–90%) were obtained from various fused imidazoles 
(products 109 and 112–115). In general, fused imidazoles benefited from the use of 
CyJohnPhos; only imidazo[1,2-a]pyrimidine coupled more efficiently with 
triphenylphosphine (product 114). Benzoxazole and benzothiazole gave 
disappointing conversions and were prone to coupling on the benzene ring if the 
amount of vinyl chloride was increased (products 116 and 117). 
Monocyclic thiazoles and oxazoles gave fair to very good yields provided that either 
of the positions C2 and C5 had been blocked (products 119–124). Coupling at the C5 
position was consistently more favorable, giving yields of 76–89% compared to 
yields of 44% and 52% at the C2 position. Unsubstituted thiazole coupled 
predominantly at the C5 position (product 118), although the double coupling 
product was also isolated in 15% yield. These results are in accordance with the 
relative energies of the C–H bonds (Section 3.5). Esters and cyano groups were well 
tolerated (products 120–123) but 2-cyano-substituted thiazole yielded a mixture of 
products (product 122). Pyridine N-oxide coupled poorly at the C2 position (product 
125). 
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Table 11. Heteroarylations of 3-chloro-2-cyclohexenone. 
 
Yields of isolated products are presented based on heteroarene. a CyJohnPhos as ligand. b 
PCy3 as ligand. Catalyst loading 5 mol-%. c 2 equivalents of vinyl chloride. d 1 equivalent 
of vinyl chloride. e At 120 °C using xylenes as solvent. f 0.5 mmol scale. 
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While the reactions proceeded well with heteroarenes bearing a basic sp2 nitrogen 
atom, other electron-rich heteroarenes such as furans and thiophenes gave 
significantly lower conversions. The dominating reaction was a vinyl chloride 
homocoupling (Scheme 23). The difference between substrates was proposed to be 
caused by a ligand effect: a basic nitrogen atom in the heterocycle possibly inhibits 
the homocoupling reaction. In that case, it was hypothesized that an unreactive 
blocked thiazole as a co-ligand could allow the reaction to proceed to completion. 
Indeed, a substoichiometric addition of the inexpensive 2,4,5-trimethylthiazole 
resulted in increased yields from non-basic heterocycles (Table 12). However, the 
yields were still far from optimal and vinyl chloride homocoupling remained a 
moderate side reaction. It is possible that better results could be obtained using a 
blocked imidazole because the fused imidazoles 109 and 112–115 inhibited 
homocoupling more efficiently than any of the thiazoles or oxazoles 116–124. For 
example, no vinyl chloride homocoupling was observed when a test reaction was run 
with tenth of the amount of imidazo[1,2-a]pyrimidine (corresponding product 114). 
Further research could be done in order to discover a convenient and easily removed 
additive. 
 
Scheme 23. Homocoupling of 3-chloro-2-cyclohexenone. 
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Table 12. Heteroarylations of 3-chloro-2-cyclohexenone with non-basic substrates. 
 
Yields of isolated products are presented based on heteroarene. 
Selected unsuccessful substrates are presented in Figure 7. Notably, monocyclic 
imidazoles 129–131 as well as 1,2,4-triazole 133 gave incomplete conversions and 
complex product mixtures. Nitro-substituted imidazole 132 was completely 
unreactive, a stark contrast to the cyano-substituted thiazoles 121 and 122. 
Benzimidazole 134, isoxazoles 135 and 136, aldehyde 137 and pyridine 138 gave no 
desired products either. 
 
Figure 7. Representative unsuccessful substrates. 
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The performance of the coupling method was also tested on 3-chloro-2-
cyclopentenone 139, a five-membered analogue of 3-chloro-2-cyclohexenone. Some 
of the same heterocycles were used as coupling partners (Table 13). 3-Chloro-2-
cyclopentenone turned out to be a slightly more challenging coupling partner, 
requiring a temperature of 120 °C and usually a higher ratio of vinyl chloride to 
heteroarene. Nevertheless, products 140–145 were obtained in fair to very good 
yields (45–88%). These results show that the developed coupling method is 
applicable to different heteroarenes as well as different vinyl chlorides. 
Table 13. Heteroarylations of 3-chloro-2-cyclopentenone. 
 
Yields of isolated products are presented based on heteroarene. a 2.5 
equivalents of vinyl chloride. b 1.5 equivalents of vinyl chloride. c 0.5 
mmol scale. 
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5 Conclusions and outlook 
A palladium-catalyzed coupling reaction to prepare heteroarene-linked 
cycloalkenones has been developed. Various electron-rich heteroarenes were 
successfully coupled with vinyl chlorides in fair to excellent yields. The method does 
not require a pre-activation of the heteroarene and it employs relatively stable vinyl 
chlorides instead of more reactive halides. Oxazoles and thiazoles were coupled 
efficiently at the C2 or C5 site provided that one of them had been blocked; coupling 
at the C4 site did not occur. 
The optimized reagent system consists of a palladium catalyst, phosphine ligand, 
carbonate base and an acid additive. The reactions were performed in toluene at 100 
°C for 20 hours. With some substrates the ligand or temperature were adjusted to 
give a better yield. As such, the method has potential uses in small-scale medicinal 
chemistry and other fine chemical industries. Some minor improvements could be 
made, such as shortening the reaction time. 
Some potential topics of further research arose during the experiments. Products 
obtained using 3-chloro-2-cyclohexenone were oxidized to corresponding phenols 
when exposed to oxygen under the reaction conditions. This reaction cascade is 
effectively a regiospecific meta-heteroarylation of phenol. It could possibly provide 
access to phenol substitution patterns that are otherwise unobtainable. Furthermore, 
while reactions of non-basic heteroarenes such as furans and thiophenes gave poor 
yields, the addition of a blocked thiazole provided somewhat promising results. More 
experiments could be run to ascertain the role of the additive and to further improve 
the results. 
  
 40 
 
6 Experimental 
Commercial reagents were used without purification as obtained from various 
suppliers. Dichloromethane and dimethylformamide were filtered through activated 
alumina using an MBRAUN SPS-800 solvent drying system. Other reaction solvents 
were dried over 3 Å molecular sieves. Solid bases were dried overnight in a 120 °C 
vacuum oven. Products were purified by normal- or reverse-phase flash 
chromatography on Teledyne Isco CombiFlash Rf equipment. Normal-phase flash 
chromatography was performed using a RediSep Rf silica column and 0–100% 
heptane/EtOAc solvent system unless otherwise stated. Reverse-phase flash 
chromatography was performed using a RediSep Rf C18 column and 10–100% 
NH4OH-water (0.5%) / acetonitrile solvent system. LC-MS data were recorded on a 
Waters Acquity UPLC and a Waters SQ mass detector. HRMS data were measured 
on a Waters Micromass Premier Q-TOF. 1H and 13C NMR spectra were recorded in 
CDCl3 (+0.03% TMS) on a Bruker Avance 400 spectrometer. The chemical shifts 
are reported in ppm relative to TMS (δ = 0.00 ppm). Melting points were determined 
on a Büchi B-545 apparatus. 
6.1 Starting materials 
 
3-Chloro-2-cyclohexenone (108). To a solution of 1,3-cyclohexanedione (1 eq, 150 
mmol, 16.8 g) and dry dichloromethane (125 mL) at 0 °C was added oxalyl chloride 
(1.2 eq, 180 mmol, 15.4 mL) dropwise over 30 minutes. The mixture was stirred for 
15 minutes and allowed to warm up to room temperature. After three hours, 120 mL 
of cold saturated aqueous NaHCO3 was added slowly. The layers were separated and 
the aqueous phase was extracted with dichloromethane (2×50 mL). Combined 
organic phases were dried with Na2SO4 and concentrated under reduced pressure. 
Crude product was distilled under reduced pressure. Colorless oil, 15.2 g (78%); 1H 
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NMR (400 MHz, CDCl3) δ ppm 2.06-2.14 (m, 2H), 2.37-2.42 (m, 2H), 2.67-2.72 (m, 
2H), 6.21 (t, J = 1.5 Hz, 1H). The spectral data was identical to previous report.80 
 
3-Chloro-2-cyclopentenone (139). To a solution of 1,3-cyclopentanedione (1 eq, 
150 mmol, 14.7 g) and dry dichloromethane (180 mL) at 0 °C was added a solution 
of oxalyl chloride (1.3 eq, 195 mmol, 16.7 mL) in dichloromethane (30 mL) 
dropwise over 30 minutes. The mixture was stirred for 15 minutes and allowed to 
warm up to room temperature. After three hours, 120 mL of cold saturated aqueous 
NaHCO3 was added slowly. The layers were separated and the aqueous phase was 
extracted with dichloromethane (2×50 mL). Combined organic phases were dried 
with Na2SO4 and concentrated under reduced pressure. Crude product was distilled 
under reduced pressure. Colorless oil, 14.9 g (85%); 1H NMR (400 MHz, CDCl3) δ 
ppm 2.57-2.60 (m, 2H), 2.87-2.91 (m, 2H), 6.24 (t, J = 1.8 Hz, 1H). The spectral data 
was identical to previous report.81 
6.2 Coupling reactions 
General procedure for reaction optimization 
An oven-dried 5 mL microwave vial was charged with a magnetic stir bar, base (1.5 
eq, 0.75 mmol), palladium acetate (0.01–0.05 eq, 0.005–0.025 mmol), acid additive 
(0.15 eq, 0.075 mmol), 3-chloro-2-cyclohexenone 108 (1−2 eq, 0.5–1 mmol) and a 
solution of imidazo[1,2-a]pyridine 107 (1 eq, 0.5 mmol), mesitylene (1 eq, 0.5 
mmol) and sieve-dried solvent (1.5 mL). The vial was flushed with nitrogen flow for 
20 seconds while stirring. The ligand (0.03–0.15 eq, 0.015–0.075 mmol) was added. 
The vial was flushed with nitrogen for a further 20 seconds and sealed. The mixture 
was stirred at room temperature for 15 minutes and then heated to 100 °C. After 20 
hours, the reaction was allowed to cool down to room temperature. 20 μL samples 
taken from the starting material solution and the final reaction mixture were 
dissolved in 1 mL acetonitrile and analyzed by LC-MS (see Appendix 1). 
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General procedure with optimized reaction conditions 
An oven-dried 20 mL microwave vial was charged with a magnetic stir bar, 
potassium carbonate (1.5 eq, 4.5 mmol, 622 mg), palladium acetate (0.02 eq, 0.06 
mmol, 13.5 mg), 2-ethylhexanoic acid (0.15 eq, 0.45 mmol, 72 µL), heterocyclic 
starting material (1 eq, 3 mmol) and sieve-dried toluene (9 mL). The vial was flushed 
with nitrogen flow for 20 seconds while stirring. Vinyl chloride starting material (1.5 
eq, 4.5 mmol) and triphenylphosphine (0.06 eq, 0.18 mmol, 47 mg) were added. The 
vial was flushed with nitrogen for a further 20 seconds and sealed. The mixture was 
stirred at room temperature for 15 minutes and then heated to 100 °C. After 20 hours, 
the reaction was allowed to cool down to room temperature. The reaction mixture 
was filtered through a Celite filter sheet, flushed with ethyl acetate and 
dichloromethane (10+20 mL) and evaporated to dryness. The crude product was 
purified with flash chromatography. The isolated products were analyzed with LC-
MS, 1H NMR and 13C NMR. See Appendix 2 for original spectra. 
If the reaction was performed on 0.5 mmol scale (see Tables 11 and 13), the 
following reagent amounts were used: potassium carbonate 0.75 mmol, 104 mg; 
palladium acetate 0.01 mmol, 2.2 mg; 2-ethylhexanoic acid 0.075 mmol, 12 µL; 
heterocyclic starting material 0.5 mmol; sieve-dried toluene 1.5 mL; vinyl chloride 
starting material 0.75 mmol; triphenylphosphine 0.03 mmol, 7.9 mg. 
 
3-(Imidazo[1,2-a]pyridin-3-yl)cyclohex-2-enone (109) was prepared according to 
the general procedure using imidazo[1,2-a]pyridine (3 mmol, 304 µL) and 3-chloro-
2-cyclohexenone 108 (4.5 mmol, 499 µL). Instead of triphenylphosphine, 
CyJohnPhos (0.18 mmol, 63 mg) was used. Crude product was purified by reverse-
phase flash chromatography using a 50 g C18 column. Yellow solid, 549 mg (86%); 
mp 96–97 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.17-2.26 (m, 2H), 2.53-2.59 (m, 
2H), 2.86-2.92 (m, 2H), 6.47 (t, J = 1.3 Hz, 1H), 6.98 (td, J = 6.9, 1.3 Hz, 1H), 7.31-
7.36 (m, 1H), 7.72 (dt, J = 9.0, 1.1 Hz, 1H), 7.98 (s, 1H), 8.55 (dt, J = 7.1, 1.1 Hz, 
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1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.4, 28.7, 37.3, 114.0, 118.7, 120.7, 
123.4, 126.1, 126.4, 137.8, 147.8, 149.0, 199.1; HRMS Calculated for C13H13N2O 
(M+1) 213.1028, found 213.1032. 
 
3-(Imidazo[1,5-a]pyridin-3-yl)cyclohex-2-enone (112) was prepared according to 
the general procedure using imidazo[1,5-a]pyridine (3 mmol, 354 mg) and 3-chloro-
2-cyclohexenone 108 (4.5 mmol, 499 µL). Instead of triphenylphosphine, 
CyJohnPhos (0.18 mmol, 63 mg) was used. Crude product was purified by reverse-
phase flash chromatography using a 30 g C18 column. Orange solid, 572 mg (90%); 
mp 78–80 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.15-2.24 (m, 2H), 2.54-2.60 (m, 
2H), 3.12 (td, J = 6.0, 1.4 Hz, 2H), 6.55 (t, J = 1.4 Hz, 1H), 6.74-6.80 (m, 1H), 6.88-
6.94 (m, 1H), 7.57 (dt, J = 9.1, 1.2 Hz, 1H), 7.66 (d, J = 0.9 Hz, 1H), 8.42-8.46 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.4, 28.3, 37.6, 114.7, 119.0, 121.0, 
122.6, 123.1, 123.8, 134.1, 135.6, 149.4, 199.9; HRMS Calculated for C13H13N2O 
(M+1) 213.1028, found 213.1042. 
 
3-(Imidazo[1,2-a]pyrazin-3-yl)cyclohex-2-enone (113) was prepared according to 
the general procedure using imidazo[1,2-a]pyrazine (3 mmol, 357 mg) and 3-chloro-
2-cyclohexenone 108 (6 mmol, 666 µL). Instead of triphenylphosphine, CyJohnPhos 
(0.18 mmol, 63 mg) was used. The reaction was performed at 120 °C in xylenes (9 
mL). Crude product was purified by reverse-phase flash chromatography using a 30 
g C18 column. Orange solid, 417 mg (65%); mp 165–167 °C; 1H NMR (400 MHz, 
CDCl3) δ ppm 2.21-2.30 (m, 2H), 2.56 - 2.62 (m, 2H), 2.90 (td, J = 6.0, 1.4 Hz, 2H), 
6.48 (t, J = 1.4 Hz, 1H), 8.06 (d, J = 5.0 Hz, 1H), 8.09 (s, 1H), 8.40 (dd, J = 4.8, 1.5 
Hz, 1H), 9.20 (d, J = 1.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.4, 28.7, 
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37.3, 118.4, 123.5, 124.5, 131.3, 138.1, 143.1, 145.0, 146.7, 198.6; HRMS 
Calculated for C12H12N3O (M+1) 214.0980, found 214.0984. 
 
3-(Imidazo[1,2-a]pyrimidin-3-yl)cyclohex-2-enone (114) was prepared according 
to the general procedure using imidazo[1,2-a]pyrimidine (3 mmol, 357 mg) and 3-
chloro-2-cyclohexenone 108 (4.5 mmol, 499 µL). Crude product was purified by 
normal-phase flash chromatography using a 40 g silica column and 40–100% 
EtOAc/MeOH solvent system and further by reverse-phase flash chromatography 
using a 50 g C18 column. Orange solid, 392 mg (61%); mp 160–164 °C; 1H NMR 
(400 MHz, CDCl3) δ ppm 2.19-2.28 (m, 2H), 2.54-2.60 (m, 2H), 2.87-2.93 (m, 2H), 
6.39 (t, J = 1.2 Hz, 1H), 7.08 (dd, J = 7.0, 4.1 Hz, 1H), 8.17 (s, 1H), 8.67 (dd, J = 
4.1, 2.0 Hz, 1H), 8.87 (dd, J = 7.1, 2.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 
22.3, 28.3, 37.3, 110.0, 121.5, 121.9, 133.8, 139.0, 147.1, 151.1, 151.3, 198.8; 
HRMS Calculated for C12H12N3O (M+1) 214.0980, found 214.0993. 
 
3-(Imidazo[1,2-b]pyridazin-3-yl)cyclohex-2-enone (115) was prepared according 
to the general procedure using imidazo[1,2-b]pyridazine (3 mmol, 357 mg) and 3-
chloro-2-cyclohexenone 108 (6 mmol, 666 µL). Instead of triphenylphosphine, 
CyJohnPhos (0.18 mmol, 63 mg) was used. Crude product was purified by reverse-
phase flash chromatography using a 30 g C18 column. Orange solid, 408 mg (64%); 
mp 181–183 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.18-2.27 (m, 2H), 2.53-2.58 
(m, 2H), 2.89-2.96 (m, 2H), 7.20 (dd, J = 9.2, 4.5 Hz, 1H), 7.65 (t, J = 1.3 Hz, 1H), 
8.03-8.07 (dd, J = 9.2, 1.7 Hz, 1H), 8.12 (s, 1H), 8.50 (dd, J = 4.4, 1.7 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ ppm 22.5, 27.0, 37.5, 118.0, 123.3, 126.10, 126.11, 
137.1, 142.7, 143.2, 145.4, 200.2; HRMS Calculated for C12H12N3O (M+1) 
214.0980, found 214.0985. 
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3-(Benzo[d]oxazol-2-yl)cyclohex-2-enone (116) was prepared according to the 
general procedure using benzo[d]oxazole (3 mmol, 357 mg) and 3-chloro-2-
cyclohexenone 108 (6 mmol, 666 µL). The reaction was performed at 120 °C in 
xylenes (9 mL). Crude product was purified by normal-phase flash chromatography 
using a 24 g silica column. Orange solid, 240 mg (38%); mp 105–106 °C; 1H NMR 
(400 MHz, CDCl3) δ ppm 2.17-2.25 (m, 2H), 2.38-2.59 (m, 2H), 2.99 (td, J = 6.1, 
1.7 Hz, 2H), 7.00 (t, J = 1.7 Hz, 1H), 7.35-7.46 (m, 2H), 7.55-7.59 (m, 1H) 7.78-7.81 
(m, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.3, 25.3, 37.8, 111.0, 120.8, 125.0, 
126.9, 129.6, 141.9, 145.1, 150.7, 161.5, 199.2; HRMS Calculated for C13H12NO2 
(M+1) 214.0868, found 214.0881. 
 
3-(Benzo[d]thiazol-2-yl)cyclohex-2-enone (117) was prepared according to the 
general procedure using benzo[d]thiazole (0.5 mmol, 68 mg) and 3-chloro-2-
cyclohexenone 108 (0.75 mmol, 83 µL). 5 mol-% palladium acetate was used (5.6 
mg). Instead of triphenylphosphine, tricyclohexylphosphine (0.075 mmol, 21 mg) 
was used. Crude product was purified by normal-phase flash chromatography using a 
12 g silica column. Light brown solid, 35 mg (31%); mp 145–147 °C; 1H NMR (400 
MHz, CDCl3) δ ppm 2.16-2.26 (m, 2H), 2.53-2.60 (m, 2H), 3.08 (td, J = 6.1, 1.6 Hz, 
2H), 6.77 (t, J = 1.6 Hz, 1H), 7.42-7.55 (m, 2H), 7.88-7.93 (m, 1H) 8.06-8.10 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.3, 26.7, 37.8, 121.8, 124.1, 126.6, 
126.7, 129.1, 135.1, 152.6, 153.8, 166.6, 199.5; HRMS Calculated for C13H12NOS 
(M+1) 230.0640, found 230.0654. 
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3-(Thiazol-5-yl)cyclohex-2-enone (118) was prepared according to the general 
procedure using thiazole (3 mmol, 213 µL) and 3-chloro-2-cyclohexenone 108 (3 
mmol, 333 µL). Crude product was purified by reverse-phase flash chromatography 
using a 50 g C18 column. Brown solid, 157 mg (29%); mp 50–55 °C; 1H NMR (400 
MHz, CDCl3) δ ppm 2.14-2.23 (m, 2H), 2.47-2.53 (m, 2H), 2.82 (td, J = 6.1, 1.4 Hz, 
2H), 6.37 (t, J = 1.4 Hz, 1H), 8.13 (s, 1H), 8.86 (s, 1H); 13C NMR (100 MHz, CDCl3) 
δ ppm 22.3, 28.1, 37.2, 125.8, 138.3, 142.8, 149.6, 155.0, 198.8; HRMS Calculated 
for C9H10NOS (M+1) 180.0483, found 180.0493. 
 
3-(2-Isobutylthiazol-5-yl)cyclohex-2-enone (119) was prepared according to the 
general procedure using 2-isobutylthiazole (3 mmol, 426 µL) and 3-chloro-2-
cyclohexenone 108 (4.5 mmol, 499 µL). Crude product was purified by reverse-
phase flash chromatography using a 50 g C18 column and further by normal-phase 
flash chromatography using a 12 g silica column. Yellow oil, 537 mg (76%); 1H 
NMR (400 MHz, CDCl3) δ ppm 1.00 (d, J = 6.7 Hz, 6H), 2.07-2.20 (m, 3H), 2.45-
2.51 (m, 2H), 2.77 (td, J = 6.1, 1.4 Hz, 2H), 2.87 (d, J = 7.2 Hz, 2H), 6.27 (t, J = 1.4 
Hz, 1H), 7.88 (s, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.3, 22.4, 27.7, 29.8, 
37.3, 42.7, 125.0, 137.5, 142.1, 150.2, 173.3, 198.9; HRMS Calculated for 
C13H18NOS (M+1) 236.1109, found 236.1110. 
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Methyl 2-methyl-5-(3-oxocyclohex-1-en-1-yl)oxazole-4-carboxylate (120) was 
prepared according to the general procedure using methyl 2-methyloxazole-4-
carboxylate (3 mmol, 423 mg) and 3-chloro-2-cyclohexenone 108 (4.5 mmol, 499 
µL). Crude product was purified by normal-phase flash chromatography using a 40 g 
silica column. Yellow solid, 611 mg (87%); mp 54–55 °C; 1H NMR (400 MHz, 
CDCl3) δ ppm 2.10-2.18 (m, 2H), 2.48-2.53 (m, 2H), 2.54 (s, 3H), 2.84 (td, J = 6.1, 
1.7 Hz, 2H), 3.94 (s, 3H), 6.87 (t, J = 1.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
ppm 13.9, 22.6, 26.6, 37.5, 52.6, 129.0, 130.8, 144.8, 152.7, 161.4, 161.9, 199.2; 
HRMS Calculated for C12H14NO4 (M+1) 236.0923, found 236.0945. 
 
2-Methyl-5-(3-oxocyclohex-1-en-1-yl)thiazole-4-carbonitrile (121) was prepared 
according to the general procedure using 2-methylthiazole-4-carbonitrile (3 mmol, 
372 mg) and 3-chloro-2-cyclohexenone 108 (4.5 mmol, 499 µL). Crude product was 
purified by reverse-phase flash chromatography using a 30 g C18 column and further 
by normal-phase flash chromatography using a 12 g silica column. White solid, 581 
mg (89%); mp 111–113 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.16-2.25 (m, 2H), 
2.49-2.54 (m, 2H), 2.74 (s, 3H), 2.93 (td, J = 3.1, 1.5 Hz, 2H), 6.47 (t, J = 1.5 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ ppm 19.6, 22.5, 28.9, 37.0, 114.3, 123.1, 129.2, 
147.1, 147.6, 167.9, 198.2; HRMS Calculated for C11H11N2OS (M+1) 219.0592, 
found 219.0606. 
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5-(3-Oxocyclohex-1-en-1-yl)thiazole-2-carbonitrile (122) was prepared according 
to the general procedure using thiazole-2-carbonitrile (3 mmol, 330 mg) and 3-
chloro-2-cyclohexenone 108 (6 mmol, 666 µL). The reaction was performed at 120 
°C in xylenes (9 mL). Crude product was purified by reverse-phase flash 
chromatography using a 50 g C18 column and further by normal-phase flash 
chromatography using a 24 g silica column. Yellow solid, 160 mg (26%); mp 134–
135 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.18-2.27 (m, 2H), 2.50-2.57 (m, 2H), 
2.81 (td, J = 6.1, 1.5 Hz, 2H), 6.43 (t, J = 1.5 Hz, 1H), 8.20 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ ppm 22.2, 28.3, 37.1, 112.3, 127.9, 137.2, 143.3, 144.0, 147.2, 
198.0; HRMS Calculated for C10H9N2OS (M+1) 205.0436, found 205.0450. 
 
Ethyl 2-(3-oxocyclohex-1-en-1-yl)oxazole-5-carboxylate (123) was prepared 
according to the general procedure using ethyl 5-oxazolecarboxylate (0.5 mmol, 61 
µL) and 3-chloro-2-cyclohexenone 108 (0.75 mmol, 83 µL). Crude product was 
purified by reverse-phase flash chromatography using a 15.5 g C18 column. White 
solid, 61 mg (52%); mp 75–76 °C; 1H NMR (400 MHz, CDCl3) δ ppm 1.41 (t, J = 
7.1 Hz, 3H), 2.14-2.22 (m, 2H), 2.51-2.56 (m, 2H), 2.88 (td, J = 6.1, 1.7 Hz, 2H), 
4.41 (q, J = 7.1 Hz, 2H), 6.93 (t, J = 1.7, 1H), 7.86 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ ppm 14.2, 22.2, 25.0, 37.6, 61.9, 129.3, 135.4, 143.4, 143.8, 157.4, 162.5, 
198.9; HRMS Calculated for C12H14NO4 (M+1) 236.0923, found 236.0930. 
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3-(5-Methylthiazol-2-yl)cyclohex-2-enone (124) was prepared according to the 
general procedure using 5-methylthiazole (3 mmol, 266 µL) and 3-chloro-2-
cyclohexenone 108 (4.5 mmol, 499 µL). Crude product was purified by reverse-
phase flash chromatography using a 50 g C18 column. Orange solid, 253 mg (44%); 
mp 48–55 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.10-2.18 (m, 2H), 2.48-2.52 (m, 
2H), 2.53 (d, J = 1.1 Hz, 3H), 2.92 (td, J = 6.1, 1.6 Hz, 2H), 6.58 (t, J = 1.6 Hz, 1H), 
7.59 (q, J = 1.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 12.3, 22.3, 26.5, 37.7, 
125.8, 137.2, 142.7, 152.3, 164.9, 199.6; HRMS Calculated for C10H12NOS (M+1) 
194.0640, found 194.0643. 
 
2-(3-Oxocyclohex-1-en-1-yl)pyridine 1-oxide (125) was prepared according to the 
general procedure using pyridine N-oxide (0.5 mmol, 48 mg) and 3-chloro-2-
cyclohexenone 108 (0.75 mmol, 83 µL). Crude product was purified by reverse-
phase flash chromatography using a 15.5 g C18 column. Yellow solid, 19 mg (20%); 
mp 107–108 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.13-2.22 (m, 2H), 2.53-2.58 
(m, 2H), 2.91 (td, J = 6.0, 1.5 Hz, 2H), 6.23 (t, J = 1.5 Hz, 1H), 7.26-7.33 (m, 3H), 
8.22-8.27 (m, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 23.1, 27.0, 37.9, 125.86, 
125.92, 125.97, 130.3, 140.4, 149.3, 155.7, 199.4; HRMS Calculated for C11H12NO2 
(M+1) 190.0868, found 190.0882. 
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3-(Benzofuran-2-yl)cyclohex-2-enone (127) was prepared according to the general 
procedure using 2,3-benzofuran (3 mmol, 331 µL) and 3-chloro-2-cyclohexenone 
108 (4.5 mmol, 499 µL). 2,4,5-Trimethylthiazole (1.5 mmol, 188 µL) was finally 
added. Crude product was purified by normal-phase flash chromatography using a 50 
g silica column. Yellow solid, 197 mg (31%); mp 100–101 °C; 1H NMR (400 MHz, 
CDCl3) δ ppm 2.12-2.21 (m, 2H), 2.49-2.54 (m, 2H), 2.75 (td, J = 6.1, 1.4 Hz, 2H), 
6.71 (t, J = 1.4 Hz, 1H), 7.06 (s, 1H), 7.22-7.27 (m, 1H), 7.34-7.39 (m, 1H), 7.47-
7.51 (m, 1H), 7.58-7.61 (m, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 22.4, 25.4, 
37.6, 108.6, 111.5, 121.7, 123.3, 123.4, 126.6, 128.2, 147.0, 153.7, 155.5, 199.3; 
HRMS Calculated for C14H13O2 (M+1) 213.0916, found 213.0911. 
 
3-(5-Methylfuran-2-yl)cyclohex-2-enone (128) was prepared according to the 
general procedure using 2-methylfuran (3 mmol, 266 µL) and 3-chloro-2-
cyclohexenone 108 (4.5 mmol, 499 µL). 2,4,5-Trimethylthiazole (1.5 mmol, 188 µL) 
was finally added. Crude product was purified by reverse-phase flash 
chromatography using a 40 g silica column. Orange solid, 115 mg (22%); mp 55–60 
°C; 1H NMR (400 MHz, CDCl3) δ ppm 2.05-2.14 (m, 2H), 2.35-2.36 (m, 3H), 2.43-
2.48 (m, 2H), 2.62 (td, J = 6.1, 1.3 Hz, 2H), 6.10-6.13 (m, 1H), 6.41-6.43 (m, 1H), 
6.65 (d, J = 3.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 13.9, 22.5, 25.2, 37.5, 
108.9, 114.2, 119.7, 147.2, 150.6, 155.8, 199.5; HRMS Calculated for C11H13O2 
(M+1) 177.0916, found 177.0910. 
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3-(Imidazo[1,2-a]pyridin-3-yl)cyclopent-2-enone (140) was prepared according to 
the general procedure using imidazo[1,2-a]pyridine (3 mmol, 304 µL) and 3-chloro-
2-cyclopentenone 139 (6 mmol, 580 µL). The reaction was performed at 120 °C in 
xylenes (9 mL). Crude product was purified by reverse-phase flash chromatography 
using a 30 g C18 column. Beige solid, 266 mg (45%); mp 239–241 °C; 1H NMR 
(400 MHz, CDCl3) δ ppm 2.55-2.60 (m, 2H), 3.22-3.27 (m, 2H), 6.48 (t, J = 1.4 Hz, 
1H), 7.11 (td, J = 6.9, 1.2 Hz, 1H), 7.41-7.46 (m, 1H), 7.79 (dt, J = 9.0, 1.1 Hz, 1H), 
8.12 (s, 1H), 8.45 (dt, J = 7.0, 1.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 29.6, 
33.3, 114.7, 118.8, 121.3, 121.5, 126.1, 127.1, 138.9, 149.4, 159.2, 208.6; HRMS 
Calculated for C12H11N2O (M+1) 199.0871, found 199.0881. 
 
3-(Imidazo[1,5-a]pyridin-3-yl)cyclopent-2-enone (141) was prepared according to 
the general procedure using imidazo[1,5-a]pyridine (3 mmol, 354 mg) and 3-chloro-
2-cyclopentenone 139 (4.5 mmol, 435 µL). The reaction was performed at 120 °C in 
xylenes (9 mL). Crude product was purified by reverse-phase flash chromatography 
using a 30 g C18 column. Yellow solid, 521 mg (88%); mp 166–170 °C; 1H NMR 
(400 MHz, CDCl3) δ ppm 2.55-2.59 (m, 2H), 3.39-3.43 (m, 2H), 6.56 (t, J = 1.6 Hz, 
1H), 6.91-6.96 (m, 1 H), 7.01-7.06 (m, 1 H), 7.66 (dt, J = 9.0, 1.2 Hz, 1H), 7.76 (d, J 
= 0.9 Hz, 1H), 8.33-8.37 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ ppm 30.2, 33.7, 
115.6, 119.1, 121.7, 123.4, 123.7, 124.2, 133.6, 134.5, 160.8, 209.5; HRMS 
Calculated for C12H11N2O (M+1) 199.0871, found 199.0878. 
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3-(Imidazo[1,2-b]pyridazin-3-yl)cyclopent-2-enone (142) was prepared according 
to the general procedure using imidazo[1,2-b]pyridazine (3 mmol, 357 mg) and 3-
chloro-2-cyclopentenone 139 (7.5 mmol, 725 µL). The reaction was performed at 
120 °C in xylenes (9 mL). Crude product was purified by reverse-phase flash 
chromatography using a 30 g C18 column. Light brown solid, 339 mg (57%); mp 
225–226 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.55-2.60 (m, 2H), 3.18-3.23 (m, 
2H), 7.26 (dd, J = 9.2, 4.5 Hz, 1H), 7.32 (t, J = 1.7 Hz, 1H), 8.09 (dd, J = 9.2, 1.7 Hz, 
1H), 8.18 (s, 1H), 8.56 (dd, J = 4.5, 1.7 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 
28.6, 33.6, 118.6, 124.8, 126.1, 126.3, 136.9, 142.8, 143.8, 158.1, 209.5; HRMS 
Calculated for C11H10N3O (M+1) 200.0824, found 200.0835. 
 
3-(2-Isobutylthiazol-5-yl)cyclopent-2-enone (143) was prepared according to the 
general procedure using 2-isobutylthiazole 3 mmol, 426 µL) and 3-chloro-2-
cyclopentenone 139 (4.5 mmol, 435 µL). The reaction was performed at 120 °C in 
xylenes (9 mL). Crude product was purified by normal-phase flash chromatography 
using a 40 g silica column. Yellow oil, 395 mg (60%); 1H NMR (400 MHz, CDCl3) δ 
ppm 1.02 (d, J = 6.7 Hz, 6H), 2.08-2.22 (m, 1H), 2.56-2.60 (m, 2H), 2.91 (d, J = 7.2 
Hz, 2H), 3.02-3.07 (m, 2H), 6.28 (t, J = 1.6 Hz, 1H), 7.95 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ ppm 22.3, 29.1, 29.9, 34.8, 42.8, 128.1, 133.3, 143.0, 163.8, 174.8, 
207.9; HRMS Calculated for C12H16NOS (M+1) 222.0953, found 222.0912. 
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2-Methyl-5-(3-oxocyclopent-1-en-1-yl)thiazole-4-carbonitrile (144) was prepared 
according to the general procedure using 2-methylthiazole-4-carbonitrile (3 mmol, 
372 mg) and 3-chloro-2-cyclopentenone 139 (6 mmol, 580 µL). The reaction was 
performed at 120 °C in xylenes (9 mL). Crude product was purified by reverse-phase 
flash chromatography using a 30 g C18 column. Light brown solid, 311 mg (51%); 
mp 141–142 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.60-2.65 (m, 2H), 2.78 (s, 3H), 
3.17-3.22 (m, 2H), 6.68 (t, J = 1.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ ppm 
19.7, 30.3, 35.0, 114.1, 124.3, 132.1, 142.9, 159.6, 169.3, 207.2; HRMS Calculated 
for C10H9N2OS (M+1) 205.0436, found 205.0457. 
 
Methyl 2-methyl-5-(3-oxocyclopent-1-en-1-yl)oxazole-4-carboxylate (145) was 
prepared according to the general procedure using methyl 2-methyloxazole-4-
carboxylate (0.5 mmol, 71 mg) and 3-chloro-2-cyclopentenone 139 (1 mmol, 97 µL). 
The reaction was performed at 120 °C in xylenes (9 mL). Crude product was purified 
by reverse-phase flash chromatography using a 15.5 g C18 column. Light brown 
solid, 73 mg (66%); mp 96–98 °C; 1H NMR (400 MHz, CDCl3) δ ppm 2.53-2.57 (m, 
2H), 2.59 (s, 3H), 3.12-3.17 (m, 2H), 3.96 (s, 3H), 7.12 (t, J = 1.9 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ ppm 14.0, 28.8, 34.5, 52.7, 132.0, 132.9, 150.5, 157.4, 161.5, 
162.4, 208.9; HRMS Calculated for C11H12NO4 (M+1) 222.0766, found 222.0785. 
  
 54 
 
7 References 
1. Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. Angew. Chem. Int. Ed. 2012, 51, 
8960-9009. 
2. Fujiwara, Y.; Moritani, I.; Danno, S.; Asano, R.; Teranishi, S. J. Am. Chem. Soc. 
1969, 91, 7166-7169. 
3. Low, J. A.; Wedam, S. B.; Lee, J. J.; Berman, A. W.; Brufsky, A.; Yang, S. X.; 
Poruchynsky, M. S.; Steinberg, S. M.; Mannan, N.; Fojo, T.; Swain, S. M. J. 
Clin. Oncol. 2005, 23, 2726-2734. 
4. Austin, W. C.; Courtney, W.; Danilewicz, J. C.; Morgan, D. H.; Conover, L. H.; 
Howes Jr., H. L.; Lynch, J. E.; McFarland, J. W.; Cornwell, R. L.; Theodorides, 
V. J. Nature 1966, 212, 1273-1274. 
5. Edwards, R. M.; Trizna, W.; Stack, E. J.; Weinstock, J. J. Pharmacol. Exp. Ther. 
1996, 276, 125-129. 
6. Jones, T. R.; Labelle, M.; Belley, M.; Champion, E.; Charette, L.; Evans, J.; 
Ford-Hutchinson, A. W.; Gauthier, J.-Y.; Lord, A.; Masson, P.; McAuliffe, M.; 
McFarlane, C. S.; Metters, K. M.; Pickett, C.; Piechuta, H.; Rochette, C.; Rodger, 
I. W.; Sawyer, N.; Young, R. N. Can. J. Physiol. Pharmacol. 1995, 73, 191-201. 
7. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; 
Deprimo, S.; Brega, N.; Massimini, G.; Armand, J.-P.; Scigalla, P.; Raymond, E. 
J. Clin. Oncol. 2006, 24, 25-35. 
8. Jarman, M.; Barrie, E.; Llera, J. M. J. Med. Chem. 1998, 41, 5375-5381. 
9. Tse, F. L. S.; Smith, H. T.; Ballard, F. H.; Nicoletti, J. Biopharm. Drug Dispos. 
1990, 11, 519-531. 
10. McTaggart, F.; Buckett, L.; Davidson, R.; Holdgate, G.; McCormick, A.; 
Schneck, D.; Smith, G.; Warwick, M. Am. J. Cardiol. 2001, 87 (5A), 28-32. 
11. Harrold, M. In Antihyperlipoproteinemics and Inhibitors of Cholesterol 
Biosynthesis; Lemke, T. L., Williams, D. A., Roche, V. F. and Zito, S. W., Eds.; 
Foye's Principles of Medicinal Chemistry; LWW: Philadelphia, 2012; Vol. 7, pp 
815-840. 
12. Jimenez, M. E.; Bush, K.; Pawlik, J.; Sower, L.; Peterson, J. W.; Gilbertson, S. R. 
Bioorg. Med. Chem. Lett. 2008, 18, 4215-4218. 
 55 
 
13. Fitzner, R.; Mena-Osteritz, E.; Walzer, K.; Pfeiffer, M.; Bäuerle, P. Adv. Funct. 
Mater. 2015, 25, 1845-1856. 
14. Zhao, Y.; He, G.; Nack, W. A.; Chen, G. Org. Lett. 2012, 14, 2948-2951. 
15. Zaitsev, V. G.; Daugulis, O. J. Am. Chem. Soc. 2005, 127, 4156-4157. 
16. Das, B.; Reddy, G. C.; Balasubramanyam, P.; Salvanna, N. Tetrahedron 2012, 
68, 300-305. 
17. Grigorjeva, L.; Daugulis, O. Angew. Chem. Int. Ed. 2014, 53, 10209-10212. 
18. Vabre, R.; Chevot, F.; Legraverend, M.; Piguel, S. J. Org. Chem. 2011, 76, 9542-
9547. 
19. Sahnoun, S.; Messaoudi, S.; Brion, J.-D.; Alami, M. Eur. J. Org. Chem. 2010, 
6097-6102. 
20. Raux, E.; Klenc, J.; Blake, A.; Sączewski, J.; Strekowski, L. Molecules 2010, 15, 
1973-1984. 
21. Tanaka, S.; Fukui, Y.; Nakagawa, N.; Murakami, K.; Murakami, T. N.; 
Koumura, N.; Mori, A. Org. Lett. 2016, 18, 650-653. 
22. Besselièvre, F.; Lebrequier, S.; Mahuteau-Betzer, F.; Piguel, S. Synthesis 2009, 
3511-3518. 
23. Liégault, B.; Lapointe, D.; Caron, L.; Vlassova, A.; Fagnou, K. J. Org. Chem. 
2009, 74, 1826-1834. 
24. Hughes, C. C.; Trauner, D. Tetrahedron 2004, 60, 9675-9686. 
25. Pivsa-Art, S.; Satoh, T.; Kawamura, Y.; Miura, M.; Nomura, M. Bull. Chem. Soc. 
Jpn. 1998, 71, 467-473. 
26. Koubachi, J.; El Kazzouli, S.; Berteina-Raboin, S.; Mouaddib, A.; Guillaumet, G. 
Synthesis 2008, 2537-2542. 
27. Chai, D. I.; Lautens, M. J. Org. Chem. 2009, 74, 3054-3061. 
28. Albicker, M. R.; Cramer, N. Angew. Chem. Int. Ed. 2009, 48, 9139-9142. 
29. Peng, J.; Shang, G.; Chen, C.; Miao, Z.; Li, B. J. Org. Chem. 2013, 78, 1242-
1248. 
30. Tang, F.; Chen, C.; Zhou, Y.; Lin, C.; Zhang, J. RSC Adv. 2014, 4, 51298-51301. 
31. Yu, Y.; Wang, Z.; Zhang, X. Sci. China Chem. 2014, 57, 276-281. 
32. Hao, W.; Wang, H.; Ye, Q.; Zhang, W.-X.; Xi, Z. Org. Lett. 2015, 17, 5674-
5677. 
 56 
 
33. Jutand, A. In Mechanisms of the Mizoroki-Heck Reaction; Oestreich, M., Ed.; 
The Mizoroki-Heck Reaction; Wiley: 2009; pp 1-50. 
34. Dieck, H. A.; Heck, R. F. J. Am. Chem. Soc. 1974, 96, 1133-1136. 
35. Zhao, Q.; Besset, T.; Poisson, T.; Bouillon, J.-P.; Pannecoucke, X. Eur. J. Org. 
Chem. 2016, 2016, 76-82. 
36. Liu, M.; Niu, Y.; Wu, Y.-F.; Ye, X.-S. Org. Lett. 2016, 18, 1836-1839. 
37. Gorelsky, S. I.; Lapointe, D.; Fagnou, K. J. Org. Chem. 2012, 77, 658-668. 
38. Gorelsky, S. I.; Lapointe, D.; Fagnou, K. J. Am. Chem. Soc. 2008, 130, 10848-
10849. 
39. Larhed, M.; Hallberg, A. In The Heck Reaction (Alkene Substitution via 
Carbopalladation–Dehydropalladation) and Related Carbopalladation 
Reactions; Negishi, E., Ed.; Handbook of Organopalladium Chemistry for 
Organic Synthesis; Wiley-Interscience: New York, 2002; Vol. 1, pp 1133-1178. 
40. Koubachi, J.; Berteina-Raboin, S.; Mouaddib, A.; Guillaumet, G. Synthesis 2009, 
271-276. 
41. Heck, R. F. J. Am. Chem. Soc. 1971, 93, 6896-6901. 
42. Wu, X.; Zhou, J. Chem. Commun. 2013, 49, 4794-4796. 
43. Izawa, Y.; Zheng, C.; Stahl, S. S. Angew. Chem. Int. Ed. 2013, 52, 3672-3675. 
44. Zhu, G.; Lu, X. Organometallics 1995, 14, 4899-4904. 
45. Zhao, H.; Ariafard, A.; Lin, Z. Organometallics 2006, 25, 812-819. 
46. Portnoy, M.; Ben-David, Y.; Milstein, D. Organometallics 1993, 12, 4734-4735. 
47. Verrier, C.; Hoarau, C.; Marsais, F. Org. Biomol. Chem. 2009, 7, 647-650. 
48. Nilsson, P.; Olofsson, K.; Larhed, M. In Focus on Regioselectivity and Product 
Outcome in Organic Synthesis; Oestreich, M., Ed.; The Mizoroki-Heck Reaction; 
Wiley: 2009; pp 133-162. 
49. Blanksby, S. J.; Ellison, G. B. Acc. Chem. Res. 2003, 36, 255-263. 
50. Grushin, V. V.; Alper, H. Chem. Rev. 1994, 94, 1047-1062. 
51. Willis, M. C.; Claverie, C. K.; Mahon, M. F. Chem. Commun. 2002, 832-833. 
52. Karabelas, K.; Westerlund, C.; Hallberg, A. J. Org. Chem. 1985, 50, 3896-3900. 
53. Campeau, L.-C.; Parisien, M.; Jean, A.; Fagnou, K. J. Am. Chem. Soc. 2006, 128, 
581-590. 
 57 
 
54. Petit, A.; Flygare, J.; Miller, A. T.; Winkel, G.; Ess, D. H. Org. Lett. 2012, 14, 
3680-3683. 
55. Leclerc, J.-P.; Fagnou, K. Angew. Chem. Int. Ed. 2006, 45, 7781-7786. 
56. Strotman, N. A.; Chobanian, H. R.; Guo, Y.; He, J.; Wilson, J. E. Org. Lett. 2010, 
12, 3578-3581. 
57. Roger, J.; Gottumukkala, A. L.; Doucet, H. ChemCatChem 2010, 2, 20-40. 
58. Lane, B. S.; Brown, M. A.; Sames, D. J. Am. Chem. Soc. 2005, 127, 8050-8057. 
59. Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. Angew. Chem. Int. 
Ed. 2012, 51, 10236-10254. 
60. Lafrance, M.; Rowley, C. N.; Woo, T. K.; Fagnou, K. J. Am. Chem. Soc. 2006, 
128, 8754-8756. 
61. Gembus, V.; Bonfanti, J.-F.; Querolle, O.; Jubault, P.; Levacher, V.; Hoarau, C. 
Org. Lett. 2012, 14, 6012-6015. 
62. Ahlers, A.; De Haro, T.; Gabor, B.; Fürstner, A. Angew. Chem. Int. Ed. 2016, 55, 
1406-1411. 
63. Gottumukkala, A. L.; Derridj, F.; Djebbar, S.; Doucet, H. Tetrahedron Lett. 
2008, 49, 2926-2930. 
64. Chen, W.; Su, C.; Huang, X. Synlett 2006, 1446-1448. 
65. Ye, S.; Liu, J.; Wu, J. Chem. Commun. 2012, 48, 5028-5030. 
66. Martino, E.; Della Volpe, S.; Terribile, E.; Benetti, E.; Sakaj, M.; Centamore, A.; 
Sala, A.; Collina, S. Bioorg. Med. Chem. Lett. 2017, 27, 701-707. 
67. Yamagishi, M.; Nishigai, K.; Ishii, A.; Hata, T.; Urabe, H. Angew. Chem. Int. Ed. 
2012, 51, 6471-6474. 
68. Yamagishi, M.; Ishii, A.; Hata, T.; Urabe, H. Heterocycles 2015, 90, 847-856. 
69. Beydoun, K.; Roger, J.; Boixel, J.; Bozec, H. L.; Guerchais, V.; Doucet, H. 
Chem. Commun. 2012, 48, 11951-11953. 
70. Yuen, O. Y.; Charoensak, M.; So, C. M.; Kuhakarn, C.; Kwong, F. Y. Chem. 
Asian J. 2015, 10, 857-861. 
71. Gao, D.-W.; Gu, Y.; Wang, S.-B.; Gu, Q.; You, S.-L. Organometallics 2016, 35, 
3227-3233. 
72. Fishwick, C. W. G.; Grigg, R.; Sridharan, V.; Virica, J. Tetrahedron 2003, 59, 
4451-4468. 
 58 
 
73. Cruz, A. C. F.; Miller, N. D.; Willis, M. C. Org. Lett. 2007, 9, 4391-4393. 
74. Karaki, F.; Ohgane, K.; Fukuda, H.; Nakamura, M.; Dodo, K.; Hashimoto, Y. 
Bioorg. Med. Chem. 2014, 22, 3587-3609. 
75. Kumpulainen, E. T. T.; Pohjakallio, A. Adv. Synth. Catal. 2014, 356, 1555-1561. 
76. Ihanainen, N. E.; Kumpulainen, E. T. T.; Koskinen, A. M. P. Eur. J. Org. Chem. 
2015, 2015, 3226-3229. 
77. Harris, R. M.; Andrews, B. I.; Clark, S.; Cooke, J. W. B.; Gray, J. C. S.; Ng, S. 
Q. Q. Org. Process Res. Dev. 2013, 17, 1239-1246. 
78. Prat, D.; Wells, A.; Hayler, J.; Sneddon, H.; McElroy, C. R.; Abou-Shehada, S.; 
Dunn, P. J. Green Chem. 2015, 18, 288-296. 
79. Fiebig, L.; Schlörer, N.; Schmalz, H.-G.; Schäfer, M. Chem. Eur. J. 2014, 20, 
4906-4910. 
80. Gomes Constantino, M.; Lacerda Jr., V.; Da Silva, G. V. J. Molecules 2002, 7, 
456-464. 
81. Eckelbarger, J. D.; Wilmot, J. T.; Epperson, M. T.; Thakur, C. S.; Shum, D.; 
Antczak, C.; Tarassishin, L.; Djaballah, H.; Gin, D. Y. Chem. Eur. J. 2008, 14, 
4293-4306. 
  
  
 59 
 
Appendices 
Appendix 1: Chromatographic analysis 
Appendix 2: NMR spectra of products 
  
 
 
Appendix 1: Chromatographic analysis 
The LC-MS measurements were calibrated using a combination of an external and 
internal standard. The external standard, a mixture of 0.2 mg/mL each expected 
component (see Table 1 below), was used to relate the UV responses of the 
components to actual molar concentrations. An inert component (mesitylene) was 
added in the reaction to normalize the concentrations in the blank sample and the 
reaction sample. All results were collected using wavelength 230 nm. 
The samples were analyzed with a 3-minute method using acetonitrile and 0.1% 
ammonia solution as solvents. The standard sample was run with a shallower 
gradient and smaller injection volume to better resolve the product and phenol peaks 
(Figure 1). In the reaction samples amounts of phenol were lower so the samples 
could be run with the default method which gave narrower peaks (Figure 2). 
 
Figure 1. UV chromatogram of the standard sample. Identified components: 1,3-
cyclohexanedione 0.10 min; imidazo[1,2-a]pyridine 0.61 min; 3-chloro-2-cyclohexenone 1.12 
min; phenol product 2.06 min; product 2.29 min. 
 
Figure 2. UV chromatogram of the reaction sample of Entry 1 (Table 9 in the text). Identified 
components: 1,3-cyclohexanedione 0.11 min; imidazo[1,2-a]pyridine 0.53 min; product 0.79 
min; phenol product 0.84 min; mesitylene 1.61 min. 
 
  
 
 
The areas in the standard sample chromatogram (Figure 1) were divided by the molar 
concentration to obtain the UV correlation factors ε (Table 1). The values are 
multiplied by 5 to account for the difference in injection volumes. Example 
calculation for imidazo[1,2-a]pyridine (ipy) below. 
εipy = 5 ∙ 
Aipy
cipy
 = 5 ∙ 
1556.10 cts
0.2
118.136
 
mol
L
 = 4595786 
cts L
mol
 
Table 1. UV correlation factors for each component. 
Component ε (cts L/mol) 
1,3-cyclohexanedione 890709 
3-chloro-2-cyclohexenone 12011449 
imidazo[1,2-a]pyridine 4595786 
product 109 9647740 
phenol product 110 25758080 
Chromatographic yields of the desired product compared to imidazo[1,2-a]pyridine 
were calculated using the following equation. Yields of the phenol product were 
calculated similarly. Results are presented in the text. Example calculation for Entry 
1 (Table 9 in the text) is shown. 
Yprod = 
[product]
1
[ipy]
0
 = 
Ames,0 Aprod,1 εipy
Ames,1 Aipy,0 εprod
 = 
5304.12 ∙ 34149.30 ∙ 4595786
3788.14 ∙ 39468.27 ∙ 9647740
 = 58% 
Starting material conversions were calculated using the following equation. Results 
are presented in the text. Example calculation for Entry 1 (Table 9 in the text) is 
shown. 
Xipy = 1 – 
[ipy]
1
[ipy]
0
 = 1 – 
Aipy,1 Ames,0
Aipy,0 Ames,1
 = 1 – 
7716.24 ∙ 5304.12
39468.27 ∙ 3788.14
 = 73% 
  
  
 
 
Appendix 2: NMR spectra of products 
3-(Imidazo[1,2-a]pyridin-3-yl)cyclohex-2-enone 109: 1H, 13C, NOESY 
3-(Imidazo[1,5-a]pyridin-3-yl)cyclohex-2-enone 112: 1H, 13C 
3-(Imidazo[1,2-a]pyrazin-3-yl)cyclohex-2-enone 113: 1H, 13C 
3-(Imidazo[1,2-a]pyrimidin-3-yl)cyclohex-2-enone 114: 1H, 13C 
3-(Imidazo[1,2-b]pyridazin-3-yl)cyclohex-2-enone 115: 1H, 13C 
3-(Benzo[d]oxazol-2-yl)cyclohex-2-enone 116: 1H, 13C 
3-(Benzo[d]thiazol-2-yl)cyclohex-2-enone 117: 1H, 13C 
3-(Thiazol-5-yl)cyclohex-2-enone 118: 1H, 13C 
3-(2-Isobutylthiazol-5-yl)cyclohex-2-enone 119: 1H, 13C 
Methyl 2-methyl-5-(3-oxocyclohex-1-en-1-yl)oxazole-4-carboxylate 120: 1H, 13C 
2-Methyl-5-(3-oxocyclohex-1-en-1-yl)thiazole-4-carbonitrile 121: 1H, 13C 
5-(3-Oxocyclohex-1-en-1-yl)thiazole-2-carbonitrile 122: 1H, 13C 
Ethyl 2-(3-oxocyclohex-1-en-1-yl)oxazole-5-carboxylate 123: 1H, 13C 
3-(5-Methylthiazol-2-yl)cyclohex-2-enone 124: 1H, 13C 
2-(3-Oxocyclohex-1-en-1-yl)pyridine 1-oxide 125: 1H, 13C 
3-(Benzofuran-2-yl)cyclohex-2-enone 127: 1H, 13C 
3-(5-Methylfuran-2-yl)cyclohex-2-enone 128: 1H, 13C 
3-(Imidazo[1,2-a]pyridin-3-yl)cyclopent-2-enone 140: 1H, 13C 
3-(Imidazo[1,5-a]pyridin-3-yl)cyclopent-2-enone 141: 1H, 13C 
3-(Imidazo[1,2-b]pyridazin-3-yl)cyclopent-2-enone 142: 1H, 13C 
3-(2-Isobutylthiazol-5-yl)cyclopent-2-enone 143: 1H, 13C 
2-Methyl-5-(3-oxocyclopent-1-en-1-yl)thiazole-4-carbonitrile 144: 1H, 13C 
Methyl 2-methyl-5-(3-oxocyclopent-1-en-1-yl)oxazole-4-carboxylate 145: 1H, 13C
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3-(Imidazo[1,2-a]pyridin-3-yl)cyclohex-2-enone 109 
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Imidazo[1,5-a]pyridin-3-yl)cyclohex-2-enone 112 
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Imidazo[1,2-a]pyrazin-3-yl)cyclohex-2-enone 113  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Imidazo[1,2-a]pyrimidin-3-yl)cyclohex-2-enone 114  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Imidazo[1,2-b]pyridazin-3-yl)cyclohex-2-enone 115  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Benzo[d]oxazol-2-yl)cyclohex-2-enone 116  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Benzo[d]thiazol-2-yl)cyclohex-2-enone 117  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Thiazol-5-yl)cyclohex-2-enone 118  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(2-Isobutylthiazol-5-yl)cyclohex-2-enone 119  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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Methyl 2-methyl-5-(3-oxocyclohex-1-en-1-yl)oxazole-4-carboxylate 120  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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2-Methyl-5-(3-oxocyclohex-1-en-1-yl)thiazole-4-carbonitrile 121  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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5-(3-Oxocyclohex-1-en-1-yl)thiazole-2-carbonitrile 122  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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Ethyl 2-(3-oxocyclohex-1-en-1-yl)oxazole-5-carboxylate 123  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(5-Methylthiazol-2-yl)cyclohex-2-enone 124  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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2-(3-Oxocyclohex-1-en-1-yl)pyridine 1-oxide 125  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
2
.1
3
2
1
2
.1
4
7
6
2
.1
5
1
2
2
.1
6
3
8
2
.1
6
8
1
2
.1
7
9
8
2
.1
9
0
7
2
.1
9
5
9
2
.4
9
3
3
2
.4
9
8
2
2
.5
0
7
4
2
.5
1
1
4
2
.5
2
1
0
2
.5
2
6
7
2
.7
2
9
0
2
.7
3
2
7
2
.7
4
4
9
2
.7
4
8
1
2
.7
5
9
5
2
.7
6
3
1
6
.7
0
5
1
6
.7
0
8
6
6
.7
1
2
0
7
.0
6
3
0
7
.2
2
5
2
7
.2
2
7
7
7
.2
4
3
3
7
.2
4
5
6
7
.2
4
7
1
7
.2
6
2
5
7
.2
6
5
2
7
.3
4
3
6
7
.3
4
6
9
7
.3
6
1
6
7
.3
6
4
5
7
.3
6
7
6
7
.3
8
2
4
7
.3
8
5
7
7
.4
7
4
8
7
.4
7
7
0
7
.4
7
9
1
7
.4
8
1
3
7
.4
9
5
6
7
.4
9
7
8
7
.4
9
9
8
7
.5
0
2
0
7
.5
8
2
5
7
.5
8
4
3
7
.5
8
5
7
7
.5
8
7
4
7
.6
0
2
0
7
.6
0
3
8
7
.6
0
5
1
7
.6
0
6
9
2
.0
5
2
.0
6
2
.0
7
0
.9
5
1
.0
0
1
.1
3
1
.0
2
1
.0
0
1
.0
0
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
2
2
.4
4
2
5
.3
5
3
7
.6
1
1
0
8
.6
2
1
1
1
.5
4
1
2
1
.7
1
1
2
3
.3
4
1
2
3
.3
8
1
2
6
.5
6
1
2
8
.2
3
1
4
6
.9
9
1
5
3
.7
2
1
5
5
.5
2
1
9
9
.3
1
3-(Benzofuran-2-yl)cyclohex-2-enone 127  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(5-Methylfuran-2-yl)cyclohex-2-enone 128  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
13C NMR (100 MHz, CDCl3) 
  
  
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
2
.5
5
9
8
2
.5
6
5
2
2
.5
6
7
8
2
.5
7
3
0
2
.5
7
8
4
2
.5
8
1
0
2
.5
8
6
1
3
.2
2
8
9
3
.2
3
2
7
3
.2
3
7
2
3
.2
4
1
7
3
.2
4
6
4
3
.2
5
0
4
3
.2
5
5
2
3
.2
5
8
9
6
.4
7
4
0
6
.4
7
7
7
6
.4
8
1
2
7
.0
8
8
4
7
.0
9
1
4
7
.1
0
5
6
7
.1
0
8
6
7
.1
2
2
8
7
.1
2
5
8
7
.4
1
4
3
7
.4
1
7
3
7
.4
3
1
4
7
.4
3
4
4
7
.4
3
6
8
7
.4
3
9
8
7
.4
5
3
9
7
.4
5
6
9
7
.7
7
1
6
7
.7
7
4
5
7
.7
7
7
2
7
.7
9
4
1
7
.7
9
7
0
7
.7
9
9
7
8
.1
2
0
6
8
.4
3
7
0
8
.4
3
9
7
8
.4
4
2
4
8
.4
5
4
5
8
.4
5
7
2
8
.4
5
9
9
2
.1
4
2
.0
5
1
.0
3
1
.0
0
0
.9
9
1
.0
0
1
.0
1
1
.0
0
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
2
9
.6
2
3
3
.2
6
1
1
4
.7
0
1
1
8
.7
6
1
2
1
.2
8
1
2
1
.4
6
1
2
6
.0
5
1
2
7
.0
7
1
3
8
.8
6
1
4
9
.3
9
1
5
9
.1
5
2
0
8
.6
0
3-(Imidazo[1,2-a]pyridin-3-yl)cyclopent-2-enone 140  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Imidazo[1,5-a]pyridin-3-yl)cyclopent-2-enone 141  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(Imidazo[1,2-b]pyridazin-3-yl)cyclopent-2-enone 142  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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3-(2-Isobutylthiazol-5-yl)cyclopent-2-enone 143  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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2-Methyl-5-(3-oxocyclopent-1-en-1-yl)thiazole-4-carbonitrile 144  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
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Methyl 2-methyl-5-(3-oxocyclopent-1-en-1-yl)oxazole-4-carboxylate 145  
1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (100 MHz, CDCl3) 
 
